




- (51) **International Patent Classification:**
C07K 14/705 (2006.01) C12N 9/04 (2006.01)
C12R 1/19 (2006.01)
- (21) **International Application Number:**
PCT/US2016/061509
- (22) **International Filing Date:**
11 November 2016 (11.11.2016)
- (25) **Filing Language:** English
- (26) **Publication Language:** English
- (30) **Priority Data:**
62/255,162 13 November 2015 (13.11.2015) US
- (71) **Applicant: PRESIDENT AND FELLOWS OF HARVARD COLLEGE** [US/US]; 17 Quincy Street, Cambridge, MA 02138 (US).
- (72) **Inventors; and**
- (71) **Applicants :** BECKWITH, Jonathan [US/US]; 8A Appleton Road, Cambridge, MA 02138 (US). BOYD, Dana [US/US]; 35 Chester Avenue, Medford, MA 02155 (US). BLAZYK, Jessica [US/US]; 4 Putname Street, #3, Somerville, MA 02143 (US). HATAHET, Feras [SY/US]; 1545 Floribunda Avenue, Burlingame, CA 94010 (US).
- (74) **Agents: SMITH, Deann, F.** et al.; Patent Group, Foley Hoag LLP, 155 Seaport Blvd., Boston, MA 02210-2600 (US).
- (81) **Designated States** (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
- (84) **Designated States** (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

[Continued on next page]

(54) **Title:** HOST CELLS AND SYSTEMS FOR MEMBRANE PROTEIN EXPRESSION

Figure 1



(57) **Abstract:** Provided herein are host cells or host cellular expression systems that express a membrane protein and methods using these to produce higher amounts of the membrane protein. The cells can be used for screening and drug discovery targeting membrane proteins. The membrane protein and the host cell comprise mutations to improve the expression. The preferred membrane protein is a mammalian vitamin K epoxide reductase (VKORc1), preferably with the mutation VKORc1-deltaAAR, G60D and other. Preferred host cell-specific mutations are in a gene selected from a disulfide bond enzyme (e.g., dsbB or dsbA), insertase (e.g., yidC), ubiquinone biosynthesis gene (e.g., ubiC or ubiE), menaquinone biosynthesis gene (e.g., menA), cytoplasmic protease (e.g., hslV or hslU), or combinations thereof.



Published:

— with international search report (Art. 21(3))

— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))

*HOST CELLS AND SYSTEMS FOR
MEMBRANE PROTEIN EXPRESSION*

CROSS-REFERENCE TO RELATED APPLICATION

5 This application claims the benefit of U.S. Provisional Application No. 62/255,162, filed on November 13, 2015; the entire contents of said application are incorporated herein in their entirety by this reference.

TECHNICAL FIELD

 The disclosure relates to the field of protein expression technologies. More
10 specifically, host cells or host cellular expression systems are provided that express a foreign membrane protein in the host cell. Also, methods are provided that use such host cells or host cellular expression systems to produce higher amounts of the membrane proteins. Further, the cells or cellular systems can be used as tools for the structural and functional characterization of membrane proteins, as well as for screening and drug discovery efforts
15 targeting membrane proteins.

BACKGROUND

 While proteins localized to biological membranes constitute about a quarter of the products of an organism's open reading frames, only 0.1% of known protein structures are membrane proteins (1, 2). The lag in our knowledge of the physiology and structural biology
20 of membrane proteins is due to many factors including the low expression levels of membrane proteins and the complex biophysical nature of their interactions at the water/lipid interface. Membrane proteins, which have one or more segments that traverse the lipid bilayer, require dedicated cellular machineries for their targeting to and integration into the membranes (3). Even though these cellular machineries have maintained conserved features
25 in all domains of life, efforts to express membrane proteins in foreign organisms have often been unsuccessful. In many cases, the overexpression of indigenous membrane proteins leads to mis-targeting and inclusion body formation, protein degradation or cell death (4).

 Promoting the correct orientation of proteins within the membrane provides an additional challenge to the insertion machinery. Proper assembly is a crucial step in the
30 folding pathway of a membrane protein since a wrong orientation could be detrimental to functioning of the protein and to the viability of the cell. The overall architecture of a membrane protein, including its final membrane topology, is achieved by topogenic signals

embedded in the amino acid sequence. Such signals include long stretches of mostly hydrophobic amino acids (around 20) that determine the portion of the protein to be embedded in the membrane. Furthermore, the abundance of positively-charged amino acids in cytoplasmic domains of membrane proteins, generally referred to as the positive-inside rule, is a major contributor to membrane protein topology (5,6).

Most membrane proteins express at low levels in non-engineered eukaryotic or bacterial cells. Different techniques to increase the expression levels of the membrane protein have been taken to enhance membrane protein surface expression in heterologous cells, including addition/deletion of receptor sequences, co-expression with interacting proteins, and treatment with pharmacological chaperones (reviewed in Dunham and Hall, 2009, Trends Biotechnol. 27:541). It remains a challenge, however, to significantly improve total yield, conformational stability and/or functionality of expressed membrane protein.

Thus, it would be advantageous to have alternative expression systems that permit heterologous expression of membrane proteins for isolation, purification, and structural studies. Likewise, it would be advantageous to have membrane proteins in a functional form for screening assays targeting membrane proteins. This would greatly facilitate the whole trajectory of drug discovery efforts on membrane proteins as therapeutic targets.

SUMMARY

Proteins embedded in biological membranes are important targets for therapeutic intervention. However, they tend to be far more challenging to deal with than soluble proteins. Provided herein is a host cell (e.g., *E. coli*) useful for the high-level expression of exogenous (e.g., foreign) membrane proteins (e.g., vitamin K epoxide reductase (VKORc1) in functional form.

Thus, one aspect of the invention relates to a host cell comprising: an exogenous nucleic acid molecule encoding a membrane protein (e.g., vitamin K epoxide reductase (VKORc1), said membrane protein comprises at least one mutation (e.g., VKORc1_{ΔAAR}); and at least one host cell-specific mutation in gene selected from a disulfide bond enzyme (e.g., *dsbB* or *dsbA*), insertase (e.g., *yidC*), ubiquinone biosynthesis gene (e.g., *ubiC* or *ubiE*), menaquinone biosynthesis gene (e.g., *menA*), or cytoplasmic protease (e.g., *hslV* or *hslU*), or combinations thereof.

In some embodiments, the host cell is a bacterial host cell.

In some embodiments, the host cell is a *Escherichia coli*.

In some embodiments, the nucleic acid molecule is derived from a mouse, rat, rabbit, hamster, gerbil, dog, cat, goat, pig, cow, horse, whale, monkey, or human.

In some embodiments, the membrane protein has at least two, three, four, five, or six mutations.

5 In some embodiments, the host cell has at least two, three, four, five, or six host cell-specific mutations.

In some embodiments, the mutation is a deletion, substitution, or insertion.

In some embodiments, the membrane protein is selected from the group consisting of vitamin K epoxide reductase (VKORc1), proteorhodopsin, G protein couple receptors,
 10 growth factor receptors, transmembrane ion channels, ,neurotransmitter transporters, serotonin and olfactory receptors, glycoprotein hormone receptors, chemokine receptors, adenosine receptors, biogenic amine receptors, melanocortin receptors, neuropeptide receptors, chemotactic receptors, somatostatin receptors, opioid receptors, melatonin receptors, calcitonin receptors, PTH/PTHrP receptors, glucagon receptors, secretin receptors,
 15 latrotoxin receptors, metabotropic glutamate receptors, calcium receptors, GABA-B receptors, pheromone receptors, histamine receptors, protease-activated receptors, rhodopsins, CXCR4, GPR3, rhodopsin, vasopressin receptor, β 1 adrenergic receptor, β 2 adrenergic receptor, β 3 adrenergic receptor, α 1 adrenergic receptors and the α 2 adrenergic receptor, M1 muscarinic receptor, M2 muscarinic receptor, M3 muscarinic receptor, M4
 20 muscarinic receptor, M5 muscarinic receptor, and angiotensin II receptors.

In some embodiments, the membrane protein is VKORc1.

In some embodiments, the VKORc1 comprises a mutation having a deletion of amino acid 31-33 (AAR) (VKORc1 Δ AAR).

In some embodiments, the VKORc1 comprises a mutation at a residue selected from
 25 the group consisting of glycine 60 to aspartic acid (G60D), cysteine 43 to alanine (C43A), cysteine 51 to alanine (C51A), cysteine 132 to alanine (C33A), valine 29 to glutamic acid (V29E), valine 29 to lysine (V29K), arginine 33 to proline (A33P), alanine 48 to serine (A48S), arginine 53 to histidine (R53H), phenylalanine 55 to serine (F55S), serine 57 to proline (S57P), serine 57 to phenylalanine (S57F), arginine 58 to histidine (R58H), serine 52
 30 to asparagine (S52N), arginine 61 to histidine (R61H), glycine 62 to aspartic acid (G62D), glycine 64 to aspartic acid (G64D), threonine 4 to isoleucine (T4I), leucine 65 to proline (L65P), asparagine 80 to aspartic acid (N80D), threonine 137 to proline (T137P), or combination thereof.

In some embodiments, the VKORc1 comprises two mutations G60D and VKORc1 Δ AAR.

In some embodiments, the at least one host cell-specific mutation is a mutation of at least one gene selected from the group consisting of a disulfide bond enzyme, insertase,
5 ubiquinone biosynthesis gene, menaquinone biosynthesis gene, and cytoplasmic protease.

In some embodiments, the disulfide bond enzyme is *dsbB* or *dsbA*.

In some embodiments, the insertase is *yidC*.

In some embodiments, the cytoplasmic protease is *hslV* or *hslU*.

In some embodiments, the ubiquinone biosynthesis gene is selected from *ubiC* or
10 *ubiE*.

In some embodiments, the menaquinone biosynthesis gene is *menA*.

In some embodiments, the *yidC* comprises a mutation at a residue selected from the group consisting of alanine 11 to threonine (A11T), threonine 362 to isoleucine (T362I), threonine 362 to alanine (T362A), threonine 362 to serine (T362S), threonine 362 to
15 phenylalanine (T362F), threonine 362 to valine (T362V), threonine 362 to leucine (T362L), threonine 362 to glutamic acid (T362E), threonine 362 to arginine (T362R), threonine 362 to asparagine (T362N), threonine 362 to aspartic acid (T362D), threonine 362 to cysteine (T362C), threonine 362 to glutamine (T362Q), threonine 362 to glycine (T362G), threonine 362 to histidine (T362H), threonine 362 to methionine (T362M), threonine 362 to proline
20 (T362P), threonine 362 to tryptophan (T362W), threonine 362 to tyrosine (T362Y), threonine 362 to lysine (T362K), arginine 366 to isoleucine (R366I), threonine 373 to isoleucine (T373I), glutamine 429 to isoleucine (Q429I), threonine 474 to isoleucine (T474I), glycine 512 to serine (G512S), serine 520 to isoleucine (S520I), asparagine 521 to isoleucine (N521I), and glutamine 527 to isoleucine (Q527I), or combination thereof.

25 In some embodiments, the *yidC* comprises a mutation at T362I.

In some embodiments, the *yidC* comprises a double mutation at T362I and T373I.

In some embodiments, the *yidC* comprises a double mutation at T362I and G512S.

In some embodiments, the *yidC* comprises a mutation at T362D, T362C, T362Q, T362G, T362H, T362M, T362P, T362W, T362Y, T362N, or T362R supplemented with a
30 plasmid coding for YidC_{WT}.

In some embodiments, the *hslV* comprises a mutation at residue cysteine 160 to tyrosine (C160Y) or threonine 163 to isoleucine (T163I).

In some embodiments, the mutation is a deletion of *hslV* or *hslU*.

In some embodiments, the mutation is a deletion of *dsbB* or *dsbA*.

In some embodiments, the *dsbA* comprises a mutation at residue cysteine 33 to alanine (C33A).

In some embodiments, the mutation is a deletion of *menA*

5 In some embodiments, the host cell further comprises a reporter.

In some embodiments, the reporter is β -galactosidase.

In some embodiments, the β -galactosidase is a disulfide-bond sensitive enzyme.

In some embodiments, the disulfide-bond sensitive enzyme is β -gal^{ds}.

10 In some embodiments, the exogenous nucleic acid molecule is under the control of a promoter.

In some embodiments, the promoter is a constitutive promoter or an inducible promoter.

In some embodiments, the inducible promoter is an isopropyl β -D thiogalactopyranoside (IPTG)-inducible promoter.

15 A cell culture of the host cell is also provided. Another aspect of the invention relates to a polypeptide expressed by said host cell or a membrane preparation of said host cell. Another aspect of the invention relates a method of inhibitor, ligand screening, drug screening, protein capturing, protein purification, immunization, or a biophysical study, wherein the improvement comprises: utilizing said host cell, for inhibitor, ligand screening, drug screening, protein capturing and purification, immunization, biophysical studies.

20 Other objects, features and advantages of the present invention will become apparent from the following detailed description. It should be understood, however, that the detailed description and the specific examples, while indicating preferred embodiments of the invention, are given by way of illustration only, since various changes and modifications within the spirit and scope of the invention will become apparent to those skilled in the art from this detailed description

BRIEF DESCRIPTION OF FIGURES

30 **Figure 1** shows disulfide bond formation in *E. coli* is promoted by *EcDsbB* and *MtbVKOR* but not by vertebrate *VKORc1*. *DsbB* and *VKOR* are inner membrane proteins promote disulfide bond formation in the bacterial cell envelop. They share similar overall reaction mechanisms and complement each other in oxidizing *DsbA*. Q stands for quinone and VK for vitamin K (also a quinone). However, *VKORc1*, the mammalian homologue of the bacterial *VKOR*, is dysfunctional when expressed in *E. coli*.

Figure 2 contains four panels, **A-D**, showing mutations in VKORc1 alone or in combination with *E.coli yidC/hslVU* mutations confer increased expression and functionality in disulfide bond formation of VKORc1. All strains except for the one with DsbB⁺ indicated are deleted for *dsbB*. VKORc1_{wt} is not expressed in *E.coli* unless changes are made to its sequence and to YidC. The expression level **Panel (A)** and disulfide bond formation activity of VKORc1 (**Panels B and C**) are dramatically enhanced (low β -galactosidase activity) upon combining these mutations. **Panel D** depicts HslV_{C160Y} and HslV_{T163I} or the deletion of either component of the HslVU protease complex enables the functional expression of VKORc1 _{Δ AAR} in $\Delta dsbB$. β -galactosidase measurements data are $\pm$ SEM ($n \geq 3$).

Figure 3 contains two panels, **A and B**, showing YidC_{T362I} and HslV_{C160Y} display synergy in increasing functional expression of VKORc1. **Panel A** depicts β -galactosidase activity in HK325(*yidC*_{wt}), FSH229 (*yidC*_{T362I}), EM190 (*hslV*_{C160Y}) or FSH231(*yidC*_{T362I}, *hslV*_{C160Y}) expressing rat VKORc1_{wt} (pJK420) and VKORc1 _{Δ AAR} (pJLB420.1). Data are $\pm$ SEM ($n \geq 3$). **Panel B** depicts expression level of VKORc1_{wt} is dramatically enhanced when expressed in *hslV*_{C160Y}.

Figure 4 contains three panels, **A-C**, showing rat VKORc1 expressed in *E.coli* is inhibited by the anticoagulants bromindione and warfarin. It also interacts in the periplasm with DsbA and with DsbA_{C33A}, the latter interaction displaying a dominant negative phenotype, inhibiting VKORc1 activity. **Panel A** depicts VKORc1 inhibition is described in Materials and Methods (below). **Panel B** depicts low agar motility plates of FSH231 co-transformed with pTrc99a (empty or carrying VKORc1 _{Δ AAR,G60D}) and pBAD43 (empty or carrying DsbA/DsbA_{C33A}). **Panel C** depicts DsbA forms a mixed disulfide with VKORc1 in *E.coli*. Immunoblots of cultures of FSH231 carrying plasmids of VKORc1 _{Δ AAR,G60D} and DsbA cysteine mutants (Materials and Methods (below)). DsbA_{C33A} forms mixed-disulfide with itself as well with several *E.coli* proteins (black stars). T7 tag antibody reacts weakly but non-specifically with some *E.coli* proteins (black asterisks).

Figure 5 shows schematics of proposed topology of rat VKORc1 and localization of charged amino acids and active site cysteines. Drawings were done using Protter (43).

Figure 6 shows recessive nature of YidC_{T362I}. The gain-of-function of VKORc1 _{Δ AAR} in the *yidC*_{T362I} strain (white color colonies) is diminished in the presence of an additional copy of wild-type (wt) *yidC* expressed from a plasmid (faint blue colonies). Serial dilutions of a *yidC*_{wt} strain (HK325) and a *yidC*_{T362I} strain (FSH229) transformed with VKORc1 _{Δ AAR}

and pBAD100, empty (E.P.) or carrying *yidC*_{wt}, are spotted on rich media agar containing X-gal, 0.2% maltose and 300 μ M IPTG.

Figure 7 shows the combination of *hslV*⁻ with *yidC*_{T362I} greatly increases the activity of VKORc1 _{Δ AAR} but not VKORc1_{wt}.

Figure 8 shows rat VKORc1 is functional in *E. coli* Δ DsbB Δ menA. Strains transformed with empty pTrc99a plasmid or carrying rat VKORc1 (pVKORc1 _{Δ AAR, G60D}) were stabbed into M63 motility agar supplemented with 0.1% NZ amines and grown overnight at 30°C.

Figure 9 shows four of the seven cysteines of VKORc1 are required for complementation of Δ dsbB. HK325 (Δ dsbB) was transformed with pTrc99a carrying various cysteine mutants of rat VKORc1 (wt or A31AR deletion "Δ").

Figure 10 contains four panels, **A-D**. **Panel A** shows YidC_{T362I} restores the periplasmic activity of artificial DsbB constructs that violate the positive-inside rule. MalF-DsbB constructs K68, R72 (KR), K68N, R72 (NR) and K68N, R72N (NN) are expressed from a pTrc promoter using 1 μ M IPTG. When one or more positive charges are removed from a cytoplasmic loop of MalF-DsbB fusion, DsbB exhibits lower periplasmic activity in HK325 (Δ dsbB, *yidC*_{wt}). This diminished activity can be restored by YidC_{T362I} mutation (FSH229: Δ dsbB, *yidC*_{T362I}). **Panel b** shows YidC_{T362I} relieves the toxicity of PR-Orange overexpression. **Panel C** shows lysate fractionation of *E. coli* strains HK325 and FSH231 expressing PR-Orange. Cells were lysed by sonication (lane 1) and spun down at 6000 $\times$ g. The supernatant (lane 2) was separated from cell debris (lane 3) and subjected to ultracentrifugation (100 000 $\times$ g). Soluble proteins (lane 4) were aspirated and the pelleted membranes were solubilized by 50 mM Tris buffer (pH8) containing 2% DDM (lane 5) and subjected to a second ultracentrifugation step (100 000 $\times$ g). DDM-insoluble membranes were solubilized by 2% SDS (lane 6). Aliquots of fractions were then mixed with 2X Laemmli sample buffer analyzed by SDS-PAGE and visualized by coomassie staining or by fluorescence imaging using Typhoon scanner utilizing the fluorescence signal originating from the mOrange2 fusion. **Panel D** shows UV-Vis spectra of DDM-solubilized membrane fractions (300-600 nm).

Figure 11 shows the structure of *E. coli* YidC (PDB:3WVF). Side chains of the hydrophilic residues lining the hydrophilic groove are shown, except for G512, the main chain is shown. Cartoons are drawn using PyMOL viewer.

Figure 12 shows chromosomal directed mutagenesis in the hydrophilic groove of YidC. Overnight cultures of *yidC* mutants (derived from HK325) carrying a VKORc1 _{Δ AAR} plasmid

were serially diluted then spotted on M63 minimal plates containing X-Gal or TCEP (0, 8 and 10 mM).

DETAILED DESCRIPTION

Definitions

5 For convenience, certain terms employed in the specification, examples, and appended claims are collected here.

The articles “a” and “an” are used herein to refer to one or to more than one (*i.e.*, to at least one) of the grammatical object of the article. By way of example, “an element” means one element or more than one element.

10 A "deletion" is defined here as a change in either amino acid or nucleotide sequence in which one or more amino acid or nucleotide residues, respectively, are absent as compared to an amino acid sequence or nucleotide sequence of a parental polypeptide or nucleic acid. Within the context of a membrane protein, a deletion can involve deletion of about 2, about 5, about 10, up to about 20, up to about 30 or up to about 50 or more amino
15 acids. A protein or a fragment thereof may contain more than one deletion.

The term “endogenous,” as used herein, refers to substances (e.g., genes) originating from within an organism, tissue, or cell. Analogously, “exogenous,” as used herein, is any material that is foreign to or comes from outside an organism, tissue, or cell, but that is present (and typically can become active) in that organism, tissue, or cell.

20 The term “host cell” and equivalent terms like “recombinant host cell,” “expression host cell,” “expression host system,” “expression system,” as used herein, is intended to refer to a cell into which a foreign or exogenous nucleic acid molecule encoding a membrane protein has been introduced, and in which chromosomal mutations or host-cell specific mutations have been engineered. It should be understood that such terms are intended to
25 refer not only to the particular subject cell but to the progeny of such a cell. Because certain modifications may occur in succeeding generations due to either mutation or environmental influences, such progeny may not, in fact, be identical to the parent cell, but are still included within the scope of the term “host cell,” as used herein. A recombinant host cell may be an isolated cell or cell line grown in culture. Particular examples are provided further herein.

30 An “insertion” or “addition” is that change in an amino acid or nucleotide sequences, which has resulted in the addition of one or more amino acid or nucleotide residues, respectively, as compared to an amino acid sequence or nucleotide sequence of a parental protein. “Insertion” generally refers to addition to one or more amino acid residues within an

amino acid sequence of a polypeptide, while "addition" can be an insertion or refer to amino acid residues added at an N- or C-terminus, or both termini. Within the context of a membrane protein or a fragment thereof, an insertion or addition is usually of about 1, about 3, about 5, about 10, up to about 20, up to about 30 or up to about 50 or more amino acids. A protein or fragment thereof may contain more than one insertion.

The "membrane protein," as used herein, refers to a protein that is attached to or associated with a membrane of a cell or an organelle. In some embodiments, the membrane protein is a polytopic membrane protein, vitamin K epoxide reductase, that perform electron transfer processes, i.e., receive electrons from thioredoxin-like proteins and transfer those electrons to membrane-localized quinones. Specific non-limiting examples are provided further in the specification.

As use herein, a "mutation" refers to a change to any substitution, deletion, addition, insertion, or genetic modification of the membrane protein, host cell, or host cell chromosomes. Said mutations may be introduced via DNA and protein recombination techniques known in the art. Said mutations may also be introduced via expression of an exogenous plasmid containing said mutations, or via bacterial transduction techniques known in the art, e.g., P1 transduction.

A "substitution," as used herein, results from the replacement of one or more amino acids or nucleotides by different amino acids or nucleotides, respectively, as compared to an amino acid sequence or nucleotide sequence of a parental protein or a fragment thereof. It is understood that a protein or a fragment thereof may have conservative amino acid substitutions which have substantially no effect on the protein's activity. By conservative substitutions is intended combinations such as gly, ala; val, ile, leu, met; asp, glu; asn, gln; ser, thr; lys, arg; cys, met; and phe, tyr, trp.

The term "compound" or "test compound" or "candidate compound" or "drug candidate compound," as used herein, describes any molecule, either naturally occurring or synthetic that is tested in an assay, such as a screening assay or drug discovery assay. As such, these compounds comprise organic or inorganic compounds. The compounds include polynucleotides, lipids or hormone analogs that are characterized by low molecular weights. Other biopolymeric organic test compounds include small peptides or peptide-like molecules (peptidomimetics) comprising from about 2 to about 40 amino acids and larger polypeptides comprising from about 40 to about 500 amino acids, such as antibodies, antibody fragments or antibody conjugates. In some embodiments, the test compounds can be inhibitors, such as

anticoagulants. Test compounds can also be protein scaffolds. For high-throughput purposes, test compound libraries may be used, such as combinatorial or randomized libraries that provide a sufficient range of diversity. Examples include, but are not limited to, natural compound libraries, allosteric compound libraries, peptide libraries, antibody fragment
5 libraries, synthetic compound libraries, fragment-based libraries, phage-display libraries, and the like. A more detailed description can be found further in the specification.

As used herein, the term "ligand" means a molecule that specifically binds to a membrane protein, either intracellularly or extracellularly. A ligand may be, without the purpose of being limitative, a protein, a (poly)peptide, a lipid, a small molecule, a protein
10 scaffold, a nucleic acid, an ion, a carbohydrate, an antibody or an antibody fragment, such as a nanobody (all as defined herein). A ligand may be synthetic or naturally occurring. A ligand also includes a "native ligand," which is a ligand that is an endogenous, natural ligand for a native protein. Usually, a membrane protein will adopt a particular conformation upon binding of a ligand. Thus, a ligand is also referred to herein as a "conformation-selective
15 ligand" or "conformation-specific ligand." The term includes agonists, full agonists, partial agonists, inverse agonists, and antagonists, binding at either the orthosteric site or at an allosteric site.

As used herein, an "agonist" refers to a ligand that, by binding a membrane protein, increases the membrane protein's activity. Full agonists are capable of maximal protein
20 stimulation; partial agonists are unable to elicit full activity even at saturating concentrations. Partial agonists can also function as "blockers" by preventing the binding of more robust agonists. An "antagonist" refers to a ligand that binds a membrane protein without stimulating any activity. An "antagonist" is also known as a "blocker" because of its ability to prevent binding of other ligands and, therefore, block agonist-induced activity. Further, an
25 "inverse agonist" refers to an antagonist that, in addition to blocking agonist effects, reduces a membrane proteins' basal or constitutive activity below that of the unliganded protein. Ligands may also be allosteric regulators. "Allosteric regulators" or otherwise "allosteric modulators," "allosteric ligands" or "effector molecules," as used herein, refer to ligands that bind at an allosteric site (that is, a regulatory site physically distinct from the protein's active
30 site) of a membrane protein, in particular a membrane protein such as Vitamin K epoxide reductase. Allosteric modulators are non-competitive because they bind membrane proteins at a different site and modify their function even if the endogenous ligand also is binding. Allosteric regulators that enhance the protein's activity are referred to herein as "allosteric

activators" or "positive allosteric modulators," whereas those that decrease the protein's activity are referred to herein as "allosteric inhibitors" or otherwise "negative allosteric modulators."

The disclosure provides engineered cells or cellular systems (cell cultures, host cells, organisms) that can express proteins, particularly membrane proteins, at higher levels either at the cellular surface or in other cell compartments. In particular, the proteins that are expressed by these cells or cellular systems are maintained or stabilized in a particular functional conformation. Further, methods are provided that use such cells or cellular systems to produce these proteins. It will be appreciated that while the disclosure has been exemplified with Vitamin K epoxide reductase, it is equally applicable to any membrane protein, especially a membrane protein that is poorly expressed and has a low stability in a recombinant host cell.

Accordingly, a first aspect of the disclosure relates to a host cell comprising: an exogenous nucleic acid molecule encoding a membrane protein, said membrane protein comprises at least one mutation; and at least one host cell-specific mutation.

The "host cell," according to the disclosure, can be of any prokaryotic organism. According to a preferred embodiment, the host cell is a bacterial cell or bacterium, such as *E. coli*. The nature of the cells used will typically depend on the ease and cost of producing the foreign membrane protein(s), the desired membrane properties, the origin of the target protein, the intended application, or any combination thereof.

By "membrane protein" is understood a protein that is attached to or associated with a membrane of a cell or an organelle. They are often subdivided into several categories including integral membrane proteins, peripheral membrane proteins and lipid-anchored proteins. Preferably, the membrane protein is an integral membrane protein that is permanently bound to the lipid bilayer and which requires a detergent or another apolar solvent to be removed. Integral membrane proteins include transmembrane proteins that are permanently attached to the lipid membrane and span across the membrane one or several times. Examples of suitable membrane proteins include receptors such as G protein coupled receptors, growth factor receptors; transmembrane ion channels such as ligand-gated and voltage gated ion channels; transmembrane transporters such as neurotransmitter transporters; enzymes; carrier proteins; ion pumps; viral membrane proteins and supramolecular complexes thereof, amongst others, serotonin and olfactory receptors, glycoprotein hormone receptors, chemokine receptors, adenosine receptors, biogenic amine

receptors, melanocortin receptors, neuropeptide receptors, chemotactic receptors, somatostatin receptors, opioid receptors, melatonin receptors, calcitonin receptors, PTH/PTHrP receptors, glucagon receptors, secretin receptors, latrotoxin receptors, metabotropic glutamate receptors, calcium receptors, GABA-B receptors, pheromone
5 receptors, histamine receptors, protease-activated receptors, rhodopsins and other G-protein coupled seven transmembrane segment receptors, CXCR4, GPR3, rhodopsin, vasopressin receptor, β 1 adrenergic receptor, β 2 adrenergic receptor, β 3 adrenergic receptor, α 1 adrenergic receptors and the α 2 adrenergic receptor, M1 muscarinic receptor, M2 muscarinic receptor, M3 muscarinic receptor, M4 muscarinic receptor, M5 muscarinic receptor,
10 angiotensin II receptors.

Depending on their intended use, membrane proteins as referred to herein can be of any species, such as fungus (including yeast), nematode, virus, insect, plant, bird (e.g., chicken, turkey), reptile, or mammal (e.g., a mouse, rat, rabbit, hamster, gerbil, dog, cat, goat, pig, cow, horse, whale, monkey, or human).

15 Notably, fragments or portions, or mutants, variants, or analogues of any of the aforementioned proteins and polypeptides are also included among the suitable proteins, polypeptides and peptides that can be produced by the cells and methods presented herein. In particular, a membrane protein, as used herein, may be any naturally occurring or non-naturally occurring (i.e., altered by man) membrane protein. Within this context, the term
20 "naturally-occurring" means a membrane protein that is naturally produced (for example, and without limitation, by a mammal, more specifically by a human, or by a virus, or by a plant, or by an insect, amongst others). Such membrane proteins are found in nature.

Analogously, the term "non-naturally occurring" means a membrane protein that is not naturally produced. Wild-type membrane proteins that have been made constitutively active
25 through mutation, and variants of naturally-occurring membrane proteins are examples of non-naturally occurring membrane proteins. Non-naturally occurring membrane proteins may have an amino acid sequence that is at least 80% identical to, at least 90% identical to, at least 95% identical to or at least 99% identical to, a naturally-occurring membrane protein. Taking the vitamin K epoxide reductase as a particular non-limiting example within the
30 scope of the disclosure, it should be clear from the above that in addition to the human vitamin K epoxide reductase, the rat vitamin K epoxide reductase or other mammalian vitamin K epoxide reductase may also be employed. In addition, the term is intended to encompass wild-type polymorphic variants and certain other active variants from a particular

species. For example, a "human vitamin K epoxide reductase " has an amino acid sequence that is at least 80%, 85%, 90%, 92%, 94%, 95%, 96%, 97%, 98%, 99% identical to (e.g., at least 95% or at least 98% identical to) the naturally occurring "human vitamin K epoxide reductase ". Further, it will be appreciated that the disclosure also envisages membrane proteins, in particular vitamin K epoxide reductase, with a loop deletion, or an N- and/or C-terminal deletion, or a substitution, or an insertion or addition in relation to its amino acid or nucleotide sequence, or any combination thereof (as defined hereinbefore), or a membrane protein in complex with another chemical entity such as one or more interacting proteins or an agonist/antagonist/inverse agonist.

Thus, according to specific embodiments, the tools and methods for membrane protein expression provided herein can be further combined with known improvements for membrane protein expression that typically involve production of variants. Examples thereof include, but are not limited to, the use of a signal sequence specific to the species of eukaryotic cell used rather than the membrane protein-specific signal sequence, the use of a truncated membrane protein versus the use of an intact protein, the use of a membrane protein with a sequence insertion, and so on. Of course, these different variations can further be combined with each other.

According to still other specific embodiments, more than one, i.e., two or more different proteins may be produced simultaneously. Preferably, at least one of the proteins is a membrane protein. The proteins may all be membrane-bound, all be secreted proteins or a mixture thereof. When more than one protein is produced, care will be taken that they can be recovered easily either separately or together. In a specific embodiment, even higher production is achieved by expressing multiple copies of the protein to be expressed, e.g., as a polyprotein.

Preferably, the produced (membrane) proteins are functional, for instance, the produced receptors remain capable of ligand binding and/or signal transduction.

The host cell, according to the disclosure, is engineered so to express a membrane protein. According to other embodiments, the expression of the membrane proteins in the host cell, as described herein, is preferably regulated by appropriate promoters. The choice of a promoter will typically depend on the nature of the host cell. The choice further depends on the desired temporal expression of a particular protein, as described herein. The proteins may be expressed constitutively or in an inducible way. Accordingly, the promoter may be a constitutive or inducible promoter. The conditions for inducing a promoter may be chosen

from the following group of inducing conditions: metabolic, or stress, or pH, or temperature, or drug inducing conditions, or other. Promoters may be derived directly from naturally occurring genes, or may be synthesized to combine regulatory sequences from different promoter regions. Preferably, the promoter is an exogenous promoter that will typically be strong enough to ensure overexpression of the protein(s).

In a preferred embodiment, the promoter is an inducible promoter. Examples of inducible promoters useful for the practice of the disclosure, in particular for bacterial cells, include, without limitation, the isopropyl β -D-thiogalactopyranoside (IPTG)-inducible promoter.

It will be appreciated that having increased stability with respect to structure and/or a particular biological activity of a membrane protein may also be a guide to the stability to other denaturants or denaturing conditions including heat, a detergent, a chaotropic agent and an extreme pH. Other methods to increase the stability of a functional conformational state of a membrane protein under non-physiological conditions can include induction by dilution, concentration, buffer composition, heating, cooling, freezing, detergent, chaotropic agent, pH. In contrast to water-soluble proteins, thermodynamic studies of membrane protein folding and stability have proven to be extremely challenging, and complicated by the difficulty of finding conditions for reversible folding. Unfolding of helical membrane proteins induced by most methods, such as thermal and chemical approaches, is irreversible as reviewed by Stanley and Fleming (2008, Archives of Biochemistry and Biophysics 469:46). The term "thermostabilize," "thermostabilizing," "increasing the thermostability of," as used herein, therefore, refers to the functional rather than to the thermodynamic properties of a membrane protein and to the protein's resistance to irreversible denaturation induced by thermal and/or chemical approaches including, but not limited to, heating, cooling, freezing, chemical denaturants, pH, detergents, salts, additives, proteases or temperature. Irreversible denaturation leads to the irreversible unfolding of the functional conformations of the protein, loss of biological activity and aggregation of the denaturated protein. The term "(thermo)stabilize," "(thermo)stabilizing," "increasing the (thermo)stability of," as used herein, applies to membrane proteins embedded in lipid particles or lipid layers (for example, lipid monolayers, lipid bilayers, and the like) and to membrane proteins that have been solubilized in detergent.

According to particularly envisaged embodiments, cell cultures of host cells of the disclosure are also provided, as well as membrane preparations derived thereof (including

the target membrane protein attached to either the cell surface membrane or retained in another subcellular membrane compartment). Membrane preparations include membrane fragments as well as membrane-detergent extracts and can be prepared according to known techniques, for example, as reviewed in detail in Cooper, 2004, J. Mol. Recognit. 17:286, incorporated herein by reference. A membrane preparation is also meant to include any liposomal composition which may comprise natural or synthetic lipids or a combination thereof. Examples of membrane or liposomal compositions include, but are not limited to, organelles, membrane preparations, Virus Like Lipoparticles, lipid layers (bilayers and monolayers), lipid vesicles, high-density lipoparticles (e.g., nanodisks), and the like.

Applications

The host cells, or cell cultures or membrane preparations derived thereof, can be used to produce higher amounts of often poorly expressed and unstable target membrane proteins, optionally stabilized in a particular conformation, either at the cellular surface or in other cell compartments. As such, they are of immediate use as research tool for a wide range of functional and/or structural studies.

Accordingly, in a further aspect, the disclosure provides a method of producing or enhancing the production of a membrane protein in a host cell comprising the steps of: (a) providing a host cell, according to the disclosure, as described hereinbefore, (b) culturing the host cell under conditions suitable for expressing the membrane protein.

During or after the protein production in the host cells, the protein or proteins of interest can be recovered from the cells. Accordingly, the methods of protein production may, optionally, also comprising the step of isolating the expressed protein, either alone, or in complex with a ligand and/or with one or more downstream interacting proteins. This typically involves recovery of the material wherein the protein(s) are present (e.g., a cell lysate or specific fraction thereof, the medium wherein the protein is secreted) and subsequent purification of the protein. Means that may be employed to this end are known to the skilled person and include specific antibodies, tags fused to the proteins, affinity purification columns, and the like.

Other applications are particularly envisaged by making direct use of the host cells or cell cultures, according to the disclosure, or by using membrane preparations derived thereof, which will be described further herein, including compound screening.

In the process of compound screening, lead optimization and drug discovery, there is a requirement for faster, more effective, less expensive and especially information-rich

screening assays that provide simultaneous information on various compound characteristics and their effects on various cellular pathways (i.e., efficacy, specificity, toxicity and drug metabolism). Thus, there is a need to quickly and inexpensively screen large numbers of compounds in order to identify new specific ligands of a protein of interest, preferably
5 conformation-selective ligands, which may be potential new drug candidates. The disclosure solves this problem by providing host cells expressing at the cellular surface or in a particular cellular membrane fraction high levels of membrane proteins. Such host cells, as well as host cell cultures or membrane preparations derived thereof, can then be used as immunogens or selection reagents for screening in a variety of contexts. One can quickly and
10 reliably screen for and differentiate between receptor agonists, inverse agonists, antagonists and/or modulators as well as inhibitors of vitamin K epoxide reductase and vitamin K epoxide reductase -dependent pathways, so increasing the likelihood of identifying a ligand with the desired pharmacological properties. Screening performance for disease indications, associated with a particular functional conformer of a target membrane protein will be
15 improved by making use of the host cells of the disclosure.

Thus, according to another embodiment, the disclosure encompasses the use of the host cells, or host cell cultures, or membrane preparations derived thereof, according to the disclosure and as described hereinbefore, in screening and/or identification programs for conformation-selective binding partners of a membrane protein, which ultimately might lead
20 to potential new drug candidates.

According to one embodiment, the disclosure envisages a method of identifying compounds capable of selectively binding to a functional conformational state of a membrane protein, the method comprising the steps of: (i) Providing a host cell or host cell culture or membrane preparation derived thereof, according to the disclosure, harboring a
25 membrane protein in a functional conformational state, and (ii) Providing a test compound, and (iii) Evaluating whether the test compound binds to the functional conformational state of the membrane protein, and (iv) Selecting a compound that selectively binds to the functional conformational state of the membrane protein.

Specific preferences for the host cells, cultures and membrane preparations thereof
30 are as defined above with respect to the first aspect of the disclosure.

Screening assays for drug discovery can be solid phase (e.g., beads, columns, slides, chips or plates) or solution phase assays, e.g., a binding assay, such as radioligand binding assays. In high-throughput assays, it is possible to screen up to several thousand different

compounds in a single day in 96-, 384- or 1536-well formats. For example, each well of a microtiter plate can be used to run a separate assay against a selected potential modulator, or, if concentration or incubation time effects are to be observed, every 5-10 wells can test a single modulator. Thus, a single standard microtiter plate can assay about 96 modulators. It is possible to assay many plates per day; assay screens for up to about 6,000, 20,000, 50,000 or more different compounds are possible today. Preferably, a screening for membrane protein conformation-specific compounds will be performed starting from host cells, or host cell cultures, or membrane preparations derived thereof.

Various methods may be used to determine binding between the stabilized membrane protein and a test compound, including, for example, enzyme linked immunosorbent assays (ELISA), surface Plasmon resonance assays, chip-based assays, immunocytofluorescence, yeast two-hybrid technology and phage display, which are common practice in the art, for example, in Sambrook et al., 2001, Molecular Cloning, A Laboratory Manual. Third Edition. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N.Y. Other methods of detecting binding between a test compound and a membrane protein include ultrafiltration with ion spray mass spectroscopy/HPLC methods or other (bio)physical and analytical methods. Fluorescence Energy Resonance Transfer (FRET) methods, for example, well known to those skilled in the art, may also be used. It will be appreciated that a bound test compound can be detected using a unique label or tag associated with the compound, such as a peptide label, a nucleic acid label, a chemical label, a fluorescent label, or a radio frequency tag, as described further herein.

The compounds to be tested can be any small chemical compound, or a macromolecule, such as a protein, a sugar, nucleic acid or lipid. Typically, test compounds will be small chemical compounds, peptides, antibodies or fragments thereof. It will be appreciated that in some instances the test compound may be a library of test compounds. In particular, high-throughput screening assays for therapeutic compounds such as agonists, antagonists or inverse agonists and/or modulators form part of the disclosure. For high-throughput purposes, compound libraries or combinatorial libraries may be used such as allosteric compound libraries, peptide libraries, antibody libraries, fragment-based libraries, synthetic compound libraries, natural compound libraries, phage-display libraries and the like. Methodologies for preparing and screening such libraries are known to those of skill in the art.

The test compound may optionally be covalently or non-covalently linked to a detectable label. Suitable detectable labels and techniques for attaching, using and detecting them will be clear to the skilled person, and include, but are not limited to, any composition detectable by spectroscopic, photochemical, biochemical, immunochemical, electrical, optical or chemical means. Useful labels include magnetic beads (e.g., dynabeads), fluorescent dyes (e.g., all Alexa Fluor dyes, fluorescein isothiocyanate, Texas red, rhodamine, green fluorescent protein and the like), radiolabels (e.g., ³H, ¹²⁵I, ³⁵S, ¹⁴C, or ³²P), enzymes (e.g., horse radish peroxidase, alkaline phosphatase), and colorimetric labels such as colloidal gold or colored glass or plastic (e.g., polystyrene, polypropylene, latex, etc.) beads. Means of detecting such labels are well known to those of skill in the art. Thus, for example, radiolabels may be detected using photographic film or scintillation counters, fluorescent markers may be detected using a photodetector to detect emitted illumination. Enzymatic labels are typically detected by providing the enzyme with a substrate and detecting the reaction product produced by the action of the enzyme on the substrate, and colorimetric labels are detected by simply visualizing the colored label. Other suitable detectable labels were described earlier within the context of the first aspect of the disclosure relating to a binding domain.

Thus, according to specific embodiments, the test compound as used in any of the above screening methods is selected from the group comprising a polypeptide, a peptide, a small molecule, a natural product, a peptidomimetic, a nucleic acid, a lipid, lipopeptide, a carbohydrate, an antibody or any fragment derived thereof, such as Fab, Fab' and F(ab')₂, Fd, single-chain Fvs (scFv), single-chain antibodies, disulfide-linked Fvs (dsFv) and fragments comprising either a VL or VH domain, a heavy chain antibody (hcAb), a single domain antibody (sdAb), a minibody, the variable domain derived from camelid heavy chain antibodies (VHH or nanobody), the variable domain of the new antigen receptors derived from shark antibodies (VNAR), a protein scaffold including an alphabody, protein A, protein G, designed ankyrin-repeat domains (DARPin), fibronectin type III repeats, anticalins, knottins, engineered CH₂ domains (nanoantibodies), as defined hereinbefore.

It may be desirable to identify and characterize natural or endogenous ligands of target membrane proteins. In particular, there is a need to "de-orphanise" vitamin K epoxide reductase for which a natural activating ligand has not been identified. Such ligands may be recovered from biological samples such as blood or tissue extract or from libraries of ligands. Thus, according to a particular embodiment, the test compound, as used in any of

the above screening methods, is provided as a biological sample. In particular, the sample can be any suitable sample taken from an individual. For example, the sample may be a body fluid sample such as blood, serum, plasma, spinal fluid.

In addition to establishing binding to a target membrane protein in a functional conformational state, it will also be desirable to determine the functional effect of a compound on the membrane protein. In particular, the host cells, host cell cultures or membrane preparations derived thereof, as described herein, can be used to screen for compounds and/or to validate hits or leads that modulate (increase or decrease) the biological activity of the membrane protein. The desired modulation in biological activity will depend on the target of choice. Taking a target vitamin K epoxide reductase as an example, the compounds may bind to the target vitamin K epoxide reductase resulting in the modulation (activation or inhibition) of the biological function of the vitamin K epoxide reductase, for example, the downstream receptor signaling. In some embodiments, the inhibitor of vitamin K epoxide reductase is derived from DsbAC33A. In some embodiments, the vitamin K epoxide reductase inhibitor is a peptide, antigen, epitope, or polypeptide derived from DsbAC33A. This modulation of vitamin K epoxide reductase signaling can occur ortho- or allosterically. The compounds may bind to the target vitamin K epoxide reductase so as to activate or increase receptor signaling; or alternatively, so as to decrease or inhibit receptor signaling. The compounds may also bind to the target vitamin K epoxide reductase in such a way that they block off the constitutive activity of the vitamin K epoxide reductase. The compounds may also bind to the target complex in such a way that they mediate allosteric modulation (e.g., bind to the vitamin K epoxide reductase at an allosteric site). In this way, the compounds may modulate the receptor function by binding to different regions in the vitamin K epoxide reductase (e.g., at allosteric sites). The compounds of the disclosure may also bind to the target vitamin K epoxide reductase in such a way that they prolong the duration of the vitamin K epoxide reductase-mediated signaling or that they enhance receptor signaling by increasing receptor-ligand affinity. Further, the compounds may also bind to the target vitamin K epoxide reductase in such a way that they inhibit or enhance the assembly of vitamin K epoxide reductase functional homomers or heteromers. The efficacy of the compounds and/or compositions comprising the same can be tested using any suitable in vitro assay, cell-based assay, in vivo assay and/or animal model known per se, or any combination thereof, depending on the specific disease or disorder involved.

It will be appreciated that the host cells and derivatives thereof, according to the disclosure, may be further engineered and are, thus, particularly useful tools for the development or improvement of cell-based assays. Cell-based assays are critical for assessing the mechanism of action of new biological targets and biological activity of chemical compounds. For example, without the purpose of being limitative, current cell-based assays for vitamin K epoxide reductase include measures of pathway activation or electron transfer processes.

Still another aspect of the disclosure, relates to a kit comprising a host cell or a host cell culture or a membrane preparation, according to the disclosure. The kit may further comprise a combination of reagents such as buffers, molecular tags, vector constructs, reference sample material, as well as a suitable solid supports, and the like. Such a kit may be useful for any of the applications of the disclosure, as described herein. For example, the kit may comprise (a library of) test compounds useful for compound screening applications.

The following examples are intended to promote a further understanding of the disclosure. While the disclosure is described herein, with reference to illustrated embodiments, it should be understood that the disclosure is not limited hereto. Those having ordinary skill in the art and access to the teachings herein will recognize additional modifications and embodiments within the scope thereof. Therefore, the disclosure is limited only by the claims attached herein.

EXAMPLES

Functional overexpression of polytopic membrane proteins, particularly when in a foreign host, is often a challenging task. Factors that negatively affect such processes are poorly understood. Using the mammalian membrane protein Vitamin K epoxide reductase (VKORc1) as a reporter, we describe a genetic selection approach allowing the isolation of *Escherichia coli* mutants capable of functionally expressing this blood-coagulation enzyme. The isolated mutants map to components of membrane protein assembly and protein quality control YidC and HslV. We show that changes in the VKORc1 sequence and in the YidC hydrophilic groove along with the inactivation of HslV promotes VKORc1 activity and dramatically increase its expression level. We hypothesize that such changes correct for mismatches in the membrane topogenic signals between *E.coli* and eukaryotic cells guiding proper membrane integration. Further, the obtained mutants allow the study of VKORc1 reaction mechanisms, inhibition by warfarin and the high-throughput screening for potential anticoagulants.

Materials and Methods:**Strains, Plasmids Media and Growth conditions:**

Strains and plasmids used in this study are listed in Table 2. Strains usually were grown on rich media (NZ-amine) at 37°C unless otherwise indicated. For experiments testing the activity of β -galactosidase in agar plates, strains were grown on minimal media M63 (M63 salts with 0.2% glucose, 1 μ g/mL vitamin B1, 1 mM MgSO₄, 65 μ g/ml X-Gal). Antibiotics used were at the following the concentrations: carbenicillin, 100 μ g/mL, chloramphenicol, 10 μ g/mL, kanamycin, 40 μ g/mL, spectinomycin, 100 μ g/mL; tetracycline, 15 μ g/mL. Glucose and L-arabinose were used at a final concentration of 0.2%, and isopropyl β -D-thiogalactopyranoside (IPTG) was used at a final concentrations of 50-300 μ M. Strains carrying PR-Orange under a pBAD promoter were grown in NZ media containing 10 μ M all-trans retinal and 0.2% arabinose at OD= 0.05.

Table 2

Strain	Genotype	Source
HK295	F' Δ ara-714 <i>galU galK</i> (lac)X74 <i>rpsL thi</i>	Laboratory collection
HK314	HK295 Δ <i>dsbA</i> ::FRT	Laboratory collection
HK320	HK295 Δ <i>dsbB</i> ::FRT	Laboratory collection
HK329	HK295 Δ <i>dsbB</i> ::FRT, Δ <i>dsbA</i> ::FRT	Laboratory collection
HK325	HK320 (malF-lacZ102, Kan ^r)	Laboratory collection
NK299	HK295 Δ <i>menA</i> ::FRT	Laboratory collection
NK300	HK320 Δ <i>menA</i> ::FRT	Laboratory collection
EcM2.1	Δ <i>mutS</i> Δ <i>recA</i> :: <i>toic Ts</i> Δ <i>bla</i> ::Zeor	Gift of George Church(38)
FSH238	HK325 YidC A11T Δ <i>tnaA</i> ::CAT	This study
FSH229	HK325 YidCT362I Δ <i>tnaA</i> ::CAT	This study
FSH240	HK325 YidC T372I Δ <i>tnaA</i> ::CAT	This study
FSH227	HK325 YidC G512S Δ <i>tnaA</i> ::CAT	This study
EM116	HK320 Δ <i>metL</i> ::FRT	This study

EM201	HK320 $\Delta metL::FRT$ <i>hsIV</i> T163I, MalF-lacZ(Kan ^r)	This study
EM203	HK320 $\Delta metL::FRT$ <i>hsIV</i> C160Y, MalF-lacZ(Kan ^r)	This study
FSH188	HK320 $\Delta hsIV::Kan$	This study
FSH193	HK320 $\Delta hsIV::FRT$	This study
FSH207	FSH193 $\Delta hsIV::FRT$, MalF-lacZ(Kan ^r)	This study
FSH199	HK320 $\Delta hsIU::Kan$	This study
EM205	FSH199 $\Delta hsIU::FRT$	This study
EM211	HK320 $\Delta hsIU::FRT$, MalF-lacZ(Kan ^r)	This study
FSH282	HK325 (YidC T362I-CAT)	This study
FSH294	HK325 (YidC T362I, G512S-CAT)	This study
FSH296	HK325 (YidC T362I, T372I-CAT)	This study
FSH380	HK325 (YidC Q429I-CAT)	This study
FSH381	HK325 (YidC T474I-CAT)	This study
FSH382	HK325 (YidC N521I-CAT)	This study
FSH383	HK325 (YidC Q526I-CAT)	This study
FSH384	HK325 (YidC S520I-CAT)	This study
FSH385	HK325 (YidC T362V-CAT)	This study
FSH386	HK325 (YidC T362L-CAT)	This study
FSH387	HK325 (YidC T362A-CAT)	This study
FSH388	HK325 (YidC T362S-CAT)	This study
FSH389	HK325 (YidC R366H-CAT)	This study
FSH391	HK325 (YidC R366I-CAT)	This study
ELM93	HK325 (YidC T362F-CAT)	This study
ELM94	HK325 (YidC T362K-CAT)	This study
ELM95	HK325 (YidC T362E-CAT)	This study
Plasmid	Description	Source
pTrc99a	pBR322 ori Amp ^r	Laboratory collection
pBAD34	pACYC184 ori Cm ^r	Laboratory collection
pBAD43	pSC101 ori Spec ^r	Laboratory collection

pBAD100	pACYC184 ori Spec ^r	This study
pELM6	pBAD100 <i>E. coli</i> YidC	This study
pJBL420	pTrec99a rat VKORc1	This study
pJBL420.1	pTrec99a rat VKORc1 ΔA31AR	This study
pEM101	pTrec99a rat VKORc1 ΔA31AR G60D	This study
pJBL420.3	pTrec99a rat VKORc1 ΔA31AR R58H	This study
pJBL420.4	pJBL420 C16A	This study
pJBL420.5	pJBL420 C43A	This study
pJBL420.6	pJBL420 C51A	This study
pJBL420.7	pJBL420 C51A	This study
pJBL420.8	pJBL420 C85A	This study
pJBL420.9	pJBL420 C96A	This study
pJBL420.10	pJBL420 C132A	This study
pJBL420.11	pJBL420 C135A	This study
pJBL420.12	pJBL420-1 C16A	This study
pJBL420.13	pJBL420-1 C43A	This study
pJBL420.14	pJBL420-1 C51A	This study
pJBL420.15	pJBL420-1 C51A	This study
pJBL420.16	pJBL420-1 C85A	This study
pJBL420.17	pJBL420-1 C96A	This study
pJBL420.18	pJBL420-1 C132A	This study
pJBL420.19	pJBL420-1 C135A	This study
pFH420	pTrec99a rat VKORc1-linker (GTGGGSGGGSGS)- T7 tag	This study
pFH421	pTrec99a rat VKORc1 ΔA31AR-linker - T7 tag	This study
pFH422	pTrec99a rat VKORc1 ΔA31AR G60D -linker -T7 tag	This study
pFH436	pTrec99a rat VKORc1 C16A ΔA31AR G60D C85A C96A- linker-T7 tag	This study
pFH437	pTrec99a rat VKORc1 C16A	This study

	C43A Δ A31AR G60D C85A C96A-linker-T7 tag	
pFH438	pTrc99a rat VKORc1 C16A C51A Δ A31AR G60D C85A C96A-linker- T7 tag	This study
pFH439	pTrc99a rat VKORc1 C16A Δ A31AR G60D C85A C96A C132A-linker -T7 tag	This study
pFH440	pTrc99a rat VKORc1 C16A C51A Δ A31AR G60D C85A C96A C132A-linker- T7 tag	This study
pFH441	pBAD43 <i>E. coli</i> DsbA-FLAG	This study
pFH442	pFH441 C33A-FLAG	This study
pFH443	pTrc99a <i>E. coli</i> YidC	This study
pFH444	pTrc99a <i>E. coli</i> MalF-DsbB	This study, (26)
pFH445	pTrc99a MalF-DsbB K68N	This study, (26)
pFH446	pTrc99a MalF-DsbB K68N,R72N	This study, (26)

VKORc1 library and Chromosomal Selection:

pTrc99a carrying human or rat VKORc1 was transformed into XL1-red according to manufacturer's instructions. After 4 cycles of mutagenesis, plasmids libraries (ca. 5×10^5 members/library) were extracted from cells and electroporated into electrocompetent HK325 and tested for motility. Motile flares were streaked twice and then retested for motility in the presence or absence of low concentration of IPTG $\pm$ warfarin. Plasmids were isolated from the motile strains, transformed into HK325, and tested again for motility.

For chromosomal mutagenesis, HK325 or FSH230 carrying pTrc99a with rat VKORc1 genes (wt or the three amino acid deletion A31AR) was treated with EMS according to Miller (36). Briefly, culture at mid-log phase was harvested and washed twice with equal volume of buffer A (1 X per liter, 4.5 g of KH_2PO_4 , 10.5 g of K_2HPO_4 , 1 g $(\text{NH}_4)_2\text{SO}_4$, and 0.5 g sodium citrate $\cdot$ 2H $_2$ O). Cells were pelleted and resuspended in half the original volume of buffer A. Subsequently, 30 μ l of the mutagen ethyl methanesulfonate (EMS) was added to 2 ml samples of culture and incubated at 37°C for 15, 30, 60, 90 and 120 min with aeration. Cells were pelleted again, washed of EMS and outgrown for 4 hours

in NZ media. Finally, the cultures were spun down, NZ media aspirated and the pelleted cells resuspended in M63 buffer before plating on M63 glucose agar containing 8-10 mM TCEP. Colonies that started to appear after 24 hours after incubation at 37°C were restreaked on similar plates and subsequently tested for motility and for white color on a minimal media plate containing X-gal.

Strains Construction and chromosomal site-directed mutagenesis:

Moving alleles between strains were done using standard P1 transduction. Spontaneous loss of plasmids carrying potentially functional VKORc1 was sought by growing the strain on M63 media in the presence of IPTG and X-gal and the absence of antibiotic selection. The appearance of blue colonies was indicative of plasmid loss, which was verified by streaking on plates containing carbenicillin. *yidC* mutants were moved into the parental strain HK325 by first introducing into the *yidC* mutant strains a chloramphenicol antibiotic resistance cassette (CAT) in place of *tnaA*, which is tightly linked to *yidC*, essentially as described in Datsenko and Wanner (37). P1 was then used to transduce the *yidC* mutation into HK325 by its linkage to chloramphenicol resistance. Single or double point mutants in the chromosomal locus of *yidC* were made by allele replacement as follows. We first made a DNA fragment of portions of *yidC* operon (by gene synthesis or PCR) carrying the intended nucleotide substitution. Subsequently, we made a fusion at the 3' end of this *yidC* DNA fragment and a CAT cassette by Gibson assembly. After PCR amplification of this DNA fusion, the resultant product was electroporated into HK325 carrying pKD46 and selected for chloramphenicol resistant colonies. At first attempt, none of the 20 colonies we screened had the intended *yidC* mutation, even though they all had the CAT cassette fused to *yidC* operon as designed. Presumably the DNA base-pair repair system had repaired the point mutation. Therefore we utilized a $\Delta mutS$, $\Delta recA$ strain (EcM2.1, George Church). This strain is impaired in homologous recombination and in base-pair mismatch correction and carries heat-inducible lambda red genes on the chromosome. We first introduced the *yidC*::CAT PCR fragment into EcM2.1 containing a plasmid coding for *yidC*_{wt}, confirmed the nucleotide substitution by sequencing, and then transduced the chromosomal *yidC*::CAT alleles using P1 into HK325, containing a plasmid coding for *yidC*_{wt} or an empty plasmid. The essentiality or the lethality of a particular amino substitution was assessed by examining the transduction efficiency. In general, lethal mutations have 50 times less transductants in HK325 containing empty plasmid. All mutations were finally confirmed by sequencing.

Construction of double mutants using *hslV* point mutants Cys160Tyr and Thr163Ile in a clean background was as follows. *metL* is required for the biosynthesis of aspartate and thus $\Delta metL$ cannot grow on minimal medium. HK320 was made *metL*⁻ by P1 transduction of *metL*::KAN from JW3911 and KAN cassette was removed by pCP20 giving EM116. P1 was grown on strains baring *hslV* mutations Cys160Tyr and Thr163Ile then used to transduce EM116 selecting on minimal plates to give EM203 and EM201. Finally, *yidC*_{T362I} was moved from FSH229 to EM203 by P1 transduction selecting on chloramphenicol. The mutations were confirmed by sequencing. Clean deletions of *hslV* and *hslU* were introduced by P1 transduction into HK320 from the Kieo collection strains JW3903 and JW3902, respectively. Then Kan cassette was removed by pCP20 before transducing the MalF-lacZ(Kan^r) to give FSH207 ($\Delta hslV$) and EM211 ($\Delta hslU$).

Motility and β -galactosidase activity:

Bacterial motility was assayed by stabbing a colony into 0.3% minimal medium Agar plates containing M63 salts, 0.2% Glucose, IPTG, and carbenicillin. Motility was examined after two days of growth at 30C. When using arabinose to induce expression from pBAD promoter, 0.5% glycerol was used instead of glucose in addition to 0.1% NZ to enhance motility.

Strains were grown at 37°C in NZ media overnight from a single colony. Next day, the overnight culture was diluted 1:100 into a fresh media containing appropriate concentration of IPTG and grown until the OD600 reached 1. Cells were collected by centrifugation and resuspended in lysis buffer to give a calculated OD600 of 5. The lysis buffer is composed of 20 mM phosphate (pH7.0), 1 X of PopCulture® (Novagen), lysozyme and Benzonase® (Millipore). Twenty microliter of the lysate was used to assay β - galactosidase activity in a total volume of 200 μ l of reaction buffer (36).

Engineering of PR-Orange:

PR-Orange was identified by fluorescence-based screening of large libraries of PR variants expressed in colonies of *E. coli*. An identical screen has been used to identify improved archaerhodopsin-based fluorescent indicators of neuronal membrane potential (39). Briefly, libraries of PR-Orange variants were assembled by a two-part overlap extension PCR. The 5' piece used in the overlap extension was prepared by error-prone PCR amplification of the template PROPS, a previously reported fluorescent indicator of membrane potential in *E. coli* (40). The 3' piece was prepared by high-fidelity PCR amplification of the fluorescent protein mOrange2 (41). The libraries were expressed in the

context of *E. coli* colonies, and those colonies with the highest ratio of PR fluorescence (~700 nm) to mOrange2 fluorescence (~560 nm) were picked and used to inoculate fresh liquid cultures. Following overnight culture, bacteria were lysed and fluorescent brightness was quantified with a microplate reader. The brightest variants were used as templates for the subsequent round of mutagenesis, DNA shuffling by StEP PCR (42), and fluorescence-based screening. After several iterative rounds of screening, we identified PR-Orange with 6 mutations relative to wild-type PR (S65F/D97N/I106V/E165V/N176D/I192N) and substantially improved fluorescence brightness.

Example 1: Mutations in the rat VKORc1 gene that enhance its expression in a form functional in *E. coli* disulfide bond formation

The bacterial proteins DsbB and VKOR and the mammalian protein VKORc1 are polytopic membrane proteins that perform quite analogous electron transfer processes. They all receive electrons from thioredoxin-like proteins and transfer those electrons to membrane-localized quinones (11).

Given these similarities between the proteins and the finding that *Mtb* VKOR can replace DsbB in *E. coli*, we asked whether rat or human VKORc1, which share 82% sequence identity, could also replace DsbB. However, when these mammalian proteins were expressed in *E. coli* by even a strong promoter, neither VKORc1 was able to substitute for DsbB. We then considered that efficient expression might be achieved by directly selecting for mutants of the VKORc1s that allowed the proteins to be functional in disulfide bond formation. There are multiple phenotypes conferred on the cell by disulfide bond formation that allow probing by various *in vivo* assays. Thus, we considered that it might be possible to screen for mutants in which VKORc1 functionally replaces *E. coli* DsbB either by enhanced expression or functionality. In order to seek such mutants, we mutagenized plasmids carrying rat or human VKORc1 expressed from an isopropyl β -D-thiogalactopyranoside (IPTG)-inducible promoter by several cycles of transformation in the mutator strain XL1-Red. The mutagenized plasmid libraries were then transformed into a $\Delta dsbB$ strain selecting for functional VKORc1 clones as indicated by restoration of bacterial motility. A $\Delta dsbB$ strain is not motile due to the absence of an essential structural disulfide bond in FlgI, a major component of the flagella machinery. Strains carrying the mutagenized plasmids were screened for motility by spotting dilutions of cultures on a soft agar plate and looking for motile flares that moved out from the culture spotted. The bacteria in the flares were purified, motility confirmed and the mutant strains tested for whether the motility was

sensitive to warfarin, a known inhibitor of VKORc1. We obtained 11 mutations in the VKORc1 gene which conferred various degrees of motility (**Table 1**). Notably, one showing the strongest motility was a deletion of amino acids 31-33 (AAR), denoted rat VKORc1 Δ AAR hereafter. These amino acids according to sequence-based algorithms for predicting

5 membrane topology are in a hydrophilic loop that follows the first TMH and would be located in the bacterial periplasm.

Table 1: Activating mutations in VKORc1. Mutations in Human (Hs) or Rat (Rn) VKORc1_{wt} conferring disulfide bond formation activity in *E. coli* Δ *dsbB* are obtained by means of plasmid libraries or EMS mutagenesis. Additional mutations with increased

10 activity are subsequently isolated when starting with a strain carrying a mutation with weak activity (i.e. RnVKORc1_{AAR} or RnVKORc1_{R58H}). Almost all of the mutations obtained are located between amino acid 29 and 80 which, according to some membrane topology prediction algorithms (POLYPHOBIUS and SPOCTOPUS (34-35)), are flanked by the first and second transmembrane helices. The vast majority of the obtained substitutions involve

15 the removal of a positively charged amino acid, or the introduction of a negatively charged one.

Table 1

Mutation	HsVKORc1 _{wt}	RnVKORc1 _{wt}	RnVKORc1 Δ A31AR	RnVKORc1 _{R58H}
V29E	1			
V29K→E		2		
Δ A31AR		8		
R33P				34
A48S			1	
R53H			7	
F55S	1	1		6
S57P				7
S57F		6		
R58H			9	
G60D		45	7	
S52N/G60D		1		
R61H			18	
G62D	3	16	2	
G64D		1	8	

T4I/G64D				18
G60D/G62D		1		
L65P		4		
N80D			2	
T137P		1		

When some of the motile mutants were further mutagenized and screened for secondary mutations that caused even greater motility, 9 additional point mutations were obtained. Remarkably, the vast majority of the amino acid substitutions are located in the loop connecting the first and second predicted TMHs, and involved either the removal of a positively charged amino acid as does VKORc1 $_{\Delta\text{AAR}}$ or the introduction of a negatively charged one (Materials and Methods (below), **Fig. 5** and **Table 1**). The subcellular localization of this loop of VKORc1, as well as the number of TMH have been controversial (15-17). However, in *Mtb*VKOR this loop contains a pair of redox-active cysteines, and by comparison with the cysteines of DsbB and *Mtb*VKOR, would have to be facing the periplasm for the protein to functionally replace DsbB.

These findings raised the possibility that the native VKORc1s may not assemble properly in the bacterial cytoplasmic membrane because of violations of the positive-inside rule preventing their ability to replace the absent DsbB. The mutations in VKORc1 may have restored an appropriate charge balance across the membrane, thus promoting proper assembly, stability and functional expression. Indeed, Western blot analysis shows that while the wild-type VKORc1 (VKORc1 $_{\text{wt}}$) is barely expressed, the mutations have a positive and additive effect on amount of protein (**Fig. 2, Panel A**, compare gel lanes 2,3 and 4). These findings suggest that VKORc1 $_{\text{wt}}$ may not assemble properly in the *E.coli* membrane leading to instability and subsequent degradation.

Example 2: Isolation of Chromosomal Mutations enhancing VKORc1 expression

Since the degree of functionality of VKORc1 in disulfide bond formation made possible by the mutations in VKORc1 was still only partial as indicated by weak restoration of *E.coli* motility, we sought chromosomal mutations in the host *E.coli* that would increase its functional expression. We devised the following selection and screening strategy: First, we constructed a ΔdsbB strain carrying a plasmid encoding either rat VKORc1 $_{\text{wt}}$ or the VKORc1 $_{\Delta\text{AAR}}$ variant. To provide a highly sensitive indicator of disulfide bond formation,

this strain (HK325) also expressed a disulfide bond-sensitive version of the enzyme β -galactosidase, β -Gal^{db_s}. β -Gal^{db_s} is the product of a fusion between the *malF* and *lacZ* genes which expresses a galactosidase exported to the periplasm by translocation signals in the membrane protein MalF. Disulfide bond formation inactivates β -Gal^{db_s} (18). As a result, on agar media containing 5-bromo-4-chloro-3-indolyl- β -D-galactopyranoside (X-Gal), strains that do not make disulfide bonds form blue colonies and those that are highly active in making disulfide bonds form white colonies. This strain was treated with the mutagen Ethyl methanesulfonate (EMS). Since $\Delta dsbB$ is unable to grow in the presence of disulfide breaking agents, the mutagenized strain is plated on minimal media agar containing such an agent, tris 2-carboxyethyl phosphine (TCEP), at a concentration sufficient to prevent growth. Colonies that survive on TCEP- containing agar are picked and screened for motility and for white colonies on X-Gal plates, indicating sufficient disulfide bond formation to inactivate β -Gal^{db_s}. Blue colonies represent strains that restore disulfide bond formation not at all or very weakly.

We saw immediately that a mutagenized strain expressing the VKORc1_{wt} did not yield colonies that survived the TCEP selection, but a strain carrying the slightly active VKORc1 _{Δ AAAR} did. Next, we sequenced the VKORc1 _{Δ AAAR} gene of the plasmid from these mutant TCEP survivors, finding that only two of the 20 mutants contained altered VKORc1 _{Δ AAAR}. These encoded an amino acid substitution G60D previously isolated in our (motility) screen for mutations activating VKORc1_{wt}. Then, assuming that at least some of the remaining strains contained chromosomal mutations influencing VKORc1 _{Δ AAAR} functional expression, we sequenced the genomic DNA of these strains on an Illumina platform. The eleven candidate strains displaying high levels of VKORc1 _{Δ AAAR} carried between 5 and 40 new mutations as a result of EMS treatment. Notably, seven strains contained missense mutations in the gene encoding the insertase *yidC*, two had mutations in the gene encoding the cytoplasmic protease *hslV* and one had missense mutations in genes for biosynthesis of ubiquinone and menaquinone (*ubiC*, *ubiE* and *menA*), molecules involved in disulfide bond formation.

Example 3: Synergy of YidC and HslV mutations in facilitating functional expression of VKORc1

To confirm that the mutations in *yidC* alone are sufficient to enhance VKORc1 _{Δ AAAR} functional assembly, we introduced these mutations by P1 transduction into the parental strain HK325 and tested for disulfide bond formation activity as judged by inactivation of β -

Gal^{db} (**Fig. 2, Panel B**). All of the strains with the transduced *yidC* mutations, except that which carried *yidC*_{A11T}, showed significantly increased VKORc1 activity as judged by increased resistance to TCEP and diminished activity of the β -galactosidase reporter. Since replacing *yidC*_{A11T} with *yidC*_{wt} abolishes the observed phenotype, this strain might require an additional yet unidentified mutation (or mutations) present to facilitate its promotion of VKORc1 activity. Given the known function of YidC, these results suggest that the altered YidC proteins are facilitating the proper assembly of VKORc1 in the *E. coli* cytoplasmic membrane. The gain of function of VKORc1 _{Δ AAR} facilitated by the chromosomal *yidC*_{T362I} can be reversed if *yidC*_{wt} is overexpressed from a plasmid (**Fig. 6**).

Next, we asked whether the individual mutations in *yidC* would have synergistic effects when combined. To this end, we utilized the lambda red recombination system to construct strains that carry double *yidC* point mutations (T362I, T373I) and (T362I, G512S). Both of the YidC double mutant strains displayed increased VKORc1 _{Δ AAR} activity compared to the single mutants, with YidC_{T362I, G512S} giving higher activity than YidC_{T362I, T373I} (**Fig. 2, Panel C**). HslV is a heat shock peptidase of the AAA+ family of peptidases. It is part of the HslVU protease complex in which HslU forms the ATPase component (19). The complex degrades defective cytoplasmic proteins under stress conditions such as heat shock. The HslV C160Y and T163I mutations obtained in our genetic selection alter two residues that are essential for the protease activity. C160 is important for the peptidase activity as well as for interaction with HslU, while T163 is involved in the essential Zn²⁺ coordination; hence both mutations appear to be loss-of-function (19-20). We introduced the C160Y and T163I *hslV* mutations into the parental unmutagenized strain by P1 transduction as well as null alleles constructed of either *hslV* or *hslU*. These strains were tested for VKORc1 _{Δ AAR} activity using the β -Gal^{db} reporter. Indeed, HslV_{C160Y} and HslV_{T163I} and clean deletions of *hslV* or *hslU* behaved similarly in rendering high activity to VKORc1 _{Δ AAR} (**Fig. 2, Panel D**). These results suggest that VKORc1, poorly assembled into the membrane, is likely recognized by the HslVU complex and degraded.

We then asked whether the *hslV* deletion and *yidC*_{T362I} were synergistic in restoring the activity of VKORc1 _{Δ AAR} in the HK325 background, by constructing a double mutant *yidC*_{T362I}, *hslV*_{C160Y} (FSH231). The combination of *hslV*⁻ with *yidC*_{T362I} greatly increases the activity of VKORc1 _{Δ AAR} but not VKORc1_{wt} (**Fig. 3, Panel A** and **Fig. 7**). However, Western blot analysis reveals that the expression (but not activity) of VKORc1_{wt} is restored to high

levels in the *hslV*_{C160Y} or *yidC*_{T362L} *hslV*_{C160Y} strains that are comparable to those seen with VKORc1_{ΔAAR} (**Fig. 3, Panel B**). These results suggest that, the failure of VKORc1 to assemble into the cytoplasmic membrane of wild-type *E. coli* in a form functional in disulfide bond formation is due to a combination of inherent properties of the protein that interfere with its proper assembly and a resultant exposure of the protein to a cellular protease.

Example 4: Functionality of VKORc1 and VKORc1_{ΔAAR} in *E. coli* strains

One reason for obtaining an *E. coli* strain expressing VKORc1 functional in disulfide bond formation was to use such a strain to readily screen for inhibitors (anticoagulants) of VKORc1 in a high-throughput blue/white agar assay in 384 well plates using the β-Gal^{db}s reporter. We recently reported this assay as a screen for inhibitors of DsbB and *Mtb*VKOR (14). We have used this assay to test whether the strains with high functional expression of VKORc1_{ΔAAR} showed sensitivity to known anticoagulants, which would indicate that VKORc1 with the removal of amino acids 31-33 (ΔAAR) still retains a key feature of the native protein. We tested the dose-dependent inhibition of VKORc1 using two different anticoagulants, warfarin and bromindione. Both anticoagulants inhibited rat VKORc1_{ΔAAR} expressed in FSH231 with bromindione showing stronger inhibitory effects than warfarin (**Fig. 4., Panel A**). This result should allow convenient studies of warfarin resistance as well as high-throughput screening for novel anticoagulants that target VKORc1 using living bacterial cells.

Next we studied the mechanism of action of VKORc1_{ΔAAR} in oxidizing DsbA. In *E. coli*, under aerobic conditions menaquinone (MK) forms less than 4% of the total quinone pool in *E. coli* (22). To test whether the observed activity of VKORc1 reflects the small amount of menaquinone (MK) that is available under aerobic condition, we constructed a Δ*dsbB* strain deficient in MK by knocking out the gene encoding the enzyme required for MK synthesis, *menA*. Based on the degree of motility, VKORc1 appears to support disulfide bond formation in a Δ*dsbB*, Δ*menA*, mutant, albeit to a slightly lesser extent than in the isogenic parental strain Δ*dsbB* (**Fig. 8**). This result implies that VKORc1_{ΔAAR} can also use ubiquinone.

We found that only the two loop cysteines and the CXXC motif, are required for VKORc1_{ΔAAR} activity in *E. coli*; loss of the other cysteines does not affect activity (**Fig. 5 and S5**). As expected, the function of VKORc1_{ΔAAR} in disulfide bond formation was dependent on *E. coli* DsbA, the presumed substrate of the now functional VKORc1_{ΔAAR}. To determine whether VKORc1_{ΔAAR} interacts directly with DsbA *in vivo*, we used a C33A

mutant of DsbA which forms a detectable stable complex with DsbB and asked whether a similar scenario occurs with VKORc1 $_{\Delta AAR}$ (23). We used the highly expressed VKORc1 $_{\Delta AAR, G60D}$ lacking all nonessential cysteines expressed in a $\Delta dsbB$, $yidC_{T362I}$, $hslV_{C160Y}$ strain (FSH231). Using a motility assay, we found that DsbA $_{C33A}$ inhibits the function of VKORc1 displaying a dominant negative phenotype in the presence of DsbA $_{wt}$ (Fig. 4, Panel B). When TCA-precipitated proteins of FSH231 strain expressing both T7-tagged VKORc1 $_{\Delta AAR, G60D}$ and FLAG-tagged DsbA $_{C33A}$ are run on a non-reducing SDS-PAGE and probed by either anti-T7 or FLAG tags antibodies, a VKORc1-DsbA complex band around 40 kDa can be seen (Fig. 4., Panel C) that is DTT-sensitive. The complex formation is also observed when using VKORc1 lacking C51, but disappears in the absence of C46 or C132, unless the removal of C132 is accompanied by the removal of C51 (Fig. 4., Panel C). These findings indicate that loop 2 (Fig. 5) is periplasmically localized since it directly receives electrons from DsbA via a thiol-disulfide exchange reaction. Thus, all tests for the mechanism of action of VKORc1 $_{\Delta AAR, G60D}$ functional in *E.coli* are essentially analogous to that of DsbB and bacterial VKOR and consistent with many of the studies on the functioning of VKORc1 in the endoplasmic reticulum (16, 24, 25).

Example 5: Can other membrane proteins non-native to *E.coli* exhibit improved membrane assembly in our strain backgrounds?

Our results showing poor functional expression of VKORc1 in *E.coli* are consistent with an explanation in which violation of the positive-inside rule is interfering with proper membrane protein assembly resulting in degradation. To test this explanation, we asked whether a mutation such as $YidC_{T362I}$ would facilitate membrane assembly of another membrane protein showing a similar pattern of positive-inside rule violation.

For this test, we used a previously reported construct of *E.coli* DsbB (MalF-DsbB) which is dependent on positively charged amino acids in cytoplasmic loops of DsbB for its proper orientation in the membrane, following the positive-inside rule (26). This construct, which contains the N-terminal MalF TM segment fused to the amino terminus of DsbB, is more sensitive to removal of those charged amino acids than DsbB itself (26). In particular, the activity of MalF-DsbB in the oxidation of periplasmic DsbA is quite dependent on the presence of positive charges, K68 and R72, in the short loop connecting TMH2 and TMH3. Presumably, the removal of positive charges disrupts the charge balance required to attain native membrane topology. However, when MalF-DsbB derivatives lacking K68 or both K68 and R72 (MalF-DsbB $_{NR}$ and MalF-DsbB $_{NN}$, respectively) are expressed from a plasmid

in a *yidC*_{T362I} strain, they both exhibit a significantly higher level of periplasmic activity in disulfide bond formation than expression of these constructs in a *yidC*_{wt} strain (**Fig. 10, Panel A**). This finding indicates that at least the domains of MalF-DsbB_{NN} which must function to oxidize DsbA in the bacterial periplasm are better localized to that compartment in the presence of YidC_{T362I}. The most straightforward interpretation of the results with VKORc1 and now MalF-DsbB is that the T362I change in YidC renders *E. coli* more permissive for the functional assembly of membrane proteins with soluble loops that violate the positive-inside rule.

We also examined the effect of the *yidC*_{T362I} mutant protein and a null mutant of *hsIV* on the expression of proteorhodopsin (PR), a 7 TMHs bacteriorhodopsin-homolog. PR-Orange is a variant of PR that was engineered to exhibit increased fluorescent brightness when expressed in *E. coli* (See materials and methods). While the amino acids composition of this protein globally follows the positive-inside rule, some of its soluble loops do so only weakly. The overexpression of PR-Orange from a plasmid with an arabinose promoter is toxic at 0.02% arabinose concentration, causing growth cessation once *E. coli* reaches mid-log phase (**Fig. 10, Panel B**). However, when expressed in a *yidC*_{T362I} strain the toxicity is markedly reduced. Expression in a *hsIV*⁻ strain is even more deleterious than in an *hsIV*⁺ strain, unless it is combined with *yidC*_{T362I}. Remarkably, formation of mild-detergent (DDM) insoluble PR-Orange seen upon overexpression in wild-type strain is also diminished in the double mutant strain *hsIV*_{C160Y}, *yidC*_{T362I}, (**Fig. 10, Panel C**). The reduction of insoluble PR-Orange is concomitant with an increase in the UV-vis absorbance of solubilized membranes, presumably as a result of accumulation of folded and retinal-incorporated protein (**Fig. 10, Panel D**). We cannot estimate how efficient that folding is.

Example 6: Effects of chromosomal directed mutagenesis for further genetic analysis of *yidC*

Based on the recent crystal structure of YidC, two of the amino acid substitutions we obtained after the EMS treatment (T362I and T373I) are located in the membrane hydrophilic groove, which is hypothesized to accommodate portions of membrane protein substrates (**Fig. 11**) (27). Since two of the mutations introduce isoleucine, we tested all possible amino acids substitutions at position 362 in the chromosomal loci of *yidC* to see whether the introduction of an isoleucine per se is required rather than the removal of the threonines to enhance the activity of VKORc1_{ΔAAR}. In addition, we tested the activity of

VKORc1 in mutant strains in which each hydrophilic residue in the membranous hydrophilic groove of YidC was mutated. All other substitutions at position 362 except S, F, A, V, L, E, and K are lethal, unless the strain is supplemented with a plasmid coding for YidC_{wt}. While T362I gave the highest activity among all (white color on X-Gal plate and TCEP resistance), T362A, and to a lesser extent T362S, also gave improved VKORc1_{ΔAAR} activity to that observed with wild type YidC (**Fig. 12**). This suggests that it is the removal of YidC T362 that is required for VKORc1_{ΔAAR} functional expression rather than the introduction of an isoleucine at that position. Since we obtained substitutions to isoleucine at 2 of the groove residues in our selection, T362I and T373I (besides G512S), we tried substituting isoleucine at each of the six other residues lining the hydrophilic groove R366, Q429, T474, S520, N521 and Q527 (27). All substitutions yielded functional YidC and, interestingly, two, Q429I and S520I, give increased functional expression of VKORc1_{ΔAAR} (**Fig. 12**). The mutations R366I, N521I and Q527I, though they resulted in functional YidC, did not support proper assembly of VKORc1_{ΔAAR} but rather abolished the very weak activity already seen with VKORc1_{ΔAAR}.

REFERENCES

1. Wallin E & von Heijne G (1998) Genome-wide analysis of integral membrane proteins from eubacterial, archaean, and eukaryotic organisms. *Protein Sci* 7(4): 1029-1038.
2. White SH (2009) Biophysical dissection of membrane proteins. *Nature* 459(7245): 344-346.
3. Dalbey RE, Wang P & Kuhn A (2011) Assembly of bacterial inner membrane proteins. *Annu Rev Biochem* 80: 161-187.
4. Wagner S, *et al* (2007) Consequences of membrane protein overexpression in escherichia coli. *Molecular & Cellular Proteomics* 6(9): 1527-1550.
5. Von Heijne G (1986) The distribution of positively charged residues in bacterial inner membrane-proteins correlates with the trans-membrane topology. *EMBO J* 5(11): 3021-3027.
6. Boyd D & Beckwith J (1990) The role of charged amino-acids in the localization of secreted and membrane-proteins. *Cell* 62(6): 1031-1033.
7. Scotti PA, *et al* (2000) YidC, the escherichia coli homologue of mitochondrial Oxa1p, is a component of the sec translocase. *EMBO J* 19(4): 542-549.
8. Serek J, *et al* (2004) Escherichia coli YidC is a membrane insertase for sec-independent proteins. *EMBO J* 23(2): 294-301.

9. Gray AN, *et al* (2011) Unbalanced charge distribution as a determinant for dependence of a subset of escherichia coli membrane proteins on the membrane insertase YidC. *MBio* 2(6): 10.1128/mBio.00238-11. Print 2011.

10. Soman R, Yuan J, Kuhn A & Dalbey RE (2014) Polarity and charge of the periplasmic loop determine the YidC and sec translocase requirement for the M13 procoat
5 lep protein. *J Biol Chem* 289(2): 1023-1032.

11. Hatahet H, Boyd D & Beckwith J (2014) Disulfide bond formation in prokaryotes: history, diversity and design. *Biochim Biophys Acta* 1844(8): 1402-1414

12. Dutton RJ, Boyd D, Berkmen M & Beckwith J (2008) Bacterial species exhibit
10 diversity in their mechanisms and capacity for protein disulfide bond formation. *Proc Natl Acad Sci U S A* 105(33): 11933-11938.

13. Li T, *et al* (2004) Identification of the gene for vitamin K epoxide reductase. *Nature* 427(6974): 541-544.

14. Landeta C, *et al* (2015) Compounds targeting disulfide bond forming enzyme
15 DsbB of gram-negative bacteria. *Nat Chem Biol* 11(4): 292-298.

15. Tie JK, Nicchitta C, von Heijne G & Stafford DW (2005) Membrane topology mapping of vitamin K epoxide reductase by in vitro translation/cotranslocation. *J Biol Chem* 280(16): 16410-16416.

16. Schulman S, Wang B, Li W & Rapoport TA (2010) Vitamin K epoxide reductase
20 prefers ER membrane-anchored thioredoxin-like redox partners. *Proc Natl Acad Sci U S A* 107(34): 15027-15032.

17. Tie J, Jin D & Stafford DW (2012) Human vitamin K epoxide reductase and its bacterial homologue have different membrane topologies and reaction mechanisms. *J Biol Chem* 287(41): 33945-33955.

25 18. Bardwell JC, McGovern K & Beckwith J (1991) Identification of a protein required for disulfide bond formation in vivo. *Cell* 67(3): 581-589.

19. Wang J, *et al* (2001) Crystal structures of the HslVU peptidase-ATPase complex reveal an ATP-dependent proteolysis mechanism. *Structure* 9(2): 177-184.

20. Yoo SJ, *et al* (1998) Effects of the cys mutations on structure and function of the
30 ATP-dependent HslVU protease in escherichia coli. the Cys287 to val mutation in HslU uncouples the ATP-dependent proteolysis by HslvU from ATP hydrolysis. *J Biol Chem* 273(36): 22929-22935.

21. Chu PH, Huang TY, Williams J & Stafford DW (2006) Purified vitamin K epoxide reductase alone is sufficient for conversion of vitamin K epoxide to vitamin K and vitamin K to vitamin KH₂. *Proc Natl Acad Sci U S A* 103(51): 19308-19313.

22. Wallace BJ & Young IG (1977) Role of quinones in electron transport to oxygen and nitrate in escherichia coli. studies with a ubiA- menA- double quinone mutant. *Biochim Biophys Acta* 461(1): 84-100.

23. Guilhot C, Jander G, Martin NL & Beckwith J (1995) Evidence that the pathway of disulfide bond formation in escherichia coli involves interactions between the cysteines of DsbB and DsbA. *Proc Natl Acad Sci U S A* 92(21): 9895-9899.

24. Rishavy MA, Usabalieva A, Hallgren KW & Berkner KL (2011) Novel insight into the mechanism of the vitamin K oxidoreductase (VKOR): Electron relay through Cys43 and Cys51 reduces VKOR to allow vitamin K reduction and facilitation of vitamin K-dependent protein carboxylation. *J Biol Chem* 286(9): 7267-7278.

25. Wang X, Dutton RJ, Beckwith J & Boyd D (2011) Membrane topology and mutational analysis of mycobacterium tuberculosis VKOR, a protein involved in disulfide bond formation and a homologue of human vitamin K epoxide reductase. *Antioxid Redox Signal* 14(8): 1413-1420.

26. Hatahet F & Ruddock LW (2013) Topological plasticity of enzymes involved in disulfide bond formation allows catalysis in either the periplasm or the cytoplasm. *J Mol Biol* 425(18): 3268-3276

27. Kumazaki K, *et al* (2014) Structural basis of sec-independent membrane protein insertion by YidC. *Nature* 509(7501): 516-520.

28. Nannenga BL & Baneyx F (2012) Folding engineering strategies for efficient membrane protein production in E.coli. *Methods Mol Biol* 899: 187-202.

29. van Bloois E, *et al* (2008) Detection of cross-links between FtsH, YidC, HflK/C suggests a linked role for these proteins in quality control upon insertion of bacterial inner membrane proteins. *FEBS Lett* 582(10): 1419-1424.

30. Li W, *et al* (2010) Structure of a bacterial homologue of vitamin K epoxide reductase. *Nature* 463(7280): 507-512.

31. Jin DY, Tie JK & Stafford DW (2007) The conversion of vitamin K epoxide to vitamin K quinone and vitamin K quinone to vitamin K hydroquinone uses the same active site cysteines. *Biochemistry* 46(24): 7279-7283.

32. Premkumar L, *et al* (2013) Rv2969c, essential for optimal growth in mycobacterium tuberculosis, is a DsbA-like enzyme that interacts with VKOR-derived peptides and has atypical features of DsbA-like disulfide oxidases. *Acta Crystallogr D Biol Crystallogr* 69(Pt 10): 1981-1994.

5 33. Duprez W, *et al* (2015) Peptide inhibitors of the escherichia coli DsbA oxidative machinery essential for bacterial virulence. *J Med Chem* 58(2): 577-587.

34. Kall L, Krogh A & Sonnhammer EL (2005) An HMM posterior decoder for sequence feature prediction that includes homology information. *Bioinformatics* 21 Suppl 1: i251-7.

10 35. Viklund H, Bernsel A, Skwark M & Elofsson A (2008) SPOCTOPUS: A combined predictor of signal peptides and membrane protein topology. *Bioinformatics* 24(24): 2928-2929.

36. Miller, JH (1992) *A Short Course in Bacterial Genetics*, (Cold Spring Harbor Laboratory Press, Plainview, NY).

15 37. Datsenko KA & Wanner BL (2000) One-step inactivation of chromosomal genes in escherichia coli K-12 using PCR products. *Proc Natl Acad Sci U S A* 97(12): 6640-6645.

38. Gregg CJ, *et al* (2014) Rational optimization of tolC as a powerful dual selectable marker for genome engineering. *Nucleic Acids Res* 42(7): 4779-4790.

39. Hochbaum, D. R., et al. (2014). "All-optical electrophysiology in mammalian
20 neurons using engineered microbial rhodopsins." *Nature Methods* 11(8): 825-833.

40. Kralj, J. M., et al. (2011). "Electrical Spiking in Escherichia coli Probed with a Fluorescent Voltage-Indicating Protein." *Science* 333(6040): 345-348.

41. Shaner, N. C., et al. (2004). "Improved monomeric red, orange and yellow fluorescent proteins derived from *Discosoma* sp. red fluorescent protein." *Nature
25 Biotechnology* 22(12): 1567-1572.

42. Zhao, H., et al. (1998). "Molecular evolution by staggered extension process (StEP) in vitro recombination." *Nature Biotechnology* 16(3): 258-261.

43. Omasits U, Ahrens CH, Müller S, Wollscheid B (2014) Protter: interactive protein feature visualization and integration with experimental proteomic data.

30 *Bioinformatics*. 15;30(6):884-886.

Incorporation by Reference

All publications, patents, and patent applications mentioned herein are hereby incorporated by reference in their entirety as if each individual publication, patent or patent

application was specifically and individually indicated to be incorporated by reference. In case of conflict, the present application, including any definitions herein, will control.

Equivalents

Those skilled in the art will recognize, or be able to ascertain using no more than
5 routine experimentation, many equivalents to the specific embodiments described herein.
Such equivalents are intended to be encompassed by the following claims.

What is claimed is:

1. A host cell comprising:
an exogenous nucleic acid molecule encoding a membrane protein, said membrane protein comprises at least one mutation; and
5 at least one host cell-specific mutation.
2. The host cell of claim 1, wherein said host cell is a bacterial host cell.
3. The host cell of any one of claims 1 to 2, wherein said host cell is a *Escherichia coli*.
4. The host cell of claim 1, wherein the nucleic acid molecule is derived from a mouse, rat, rabbit, hamster, gerbil, dog, cat, goat, pig, cow, horse, whale, monkey, or human.
- 10 5. The host cell of claim 1, wherein the membrane protein has at least two, three, four, five, or six mutations.
6. The host cell of claim 1, wherein the host cell has at least two, three, four, five, or six host cell-specific mutations.
7. The host cell of any one of claims 5 to 6, wherein the mutation is a deletion,
15 substitution, or insertion.
8. The host cell of claim 1, wherein the membrane protein is selected from the group consisting of vitamin K epoxide reductase (VKORc1), proteorhodopsin, G protein coupled receptors, growth factor receptors, transmembrane ion channels, neurotransmitter transporters, serotonin and olfactory receptors, glycoprotein hormone receptors, chemokine
20 receptors, adenosine receptors, biogenic amine receptors, melanocortin receptors, neuropeptide receptors, chemotactic receptors, somatostatin receptors, opioid receptors, melatonin receptors, calcitonin receptors, PTH/PTHrP receptors, glucagon receptors, secretin receptors, latrotoxin receptors, metabotropic glutamate receptors, calcium receptors, GABA-B receptors, pheromone receptors, histamine receptors, protease-activated receptors,
25 rhodopsins, CXCR4, GPR3, rhodopsin, vasopressin receptor, β 1 adrenergic receptor, β 2 adrenergic receptor, β 3 adrenergic receptor, α 1 adrenergic receptors and the α 2 adrenergic receptor, M1 muscarinic receptor, M2 muscarinic receptor, M3 muscarinic receptor, M4 muscarinic receptor, M5 muscarinic receptor, and angiotensin II receptors.
9. The host cell of claim 8, wherein the membrane protein is VKORc1.
- 30 10. The host cell of any one of claims 9, wherein the VKORc1 comprises a mutation having a deletion of amino acid 31-33 (AAR) (VKORc1 Δ AAR).
11. The host cell of any one of claims 9 to 10, wherein the VKORc1 comprises a mutation at a residue selected from the group consisting of glycine 60 to aspartic acid

(G60D), cysteine 43 to alanine (C43A), cysteine 51 to alanine (C51A), cysteine 132 to alanine (C33A), valine 29 to glutamic acid (V29E), valine 29 to lysine (V29K), arginine 33 to proline (A33P), alanine 48 to serine (A48S), arginine 53 to histidine (R53H), phenylalanine 55 to serine (F55S), serine 57 to proline (S57P), serine 57 to phenylalanine (S57F), arginine 58 to histidine (R58H), serine 52 to asparagine (S52N), arginine 61 to histidine (R61H), glycine 62 to aspartic acid (G62D), glycine 64 to aspartic acid (G64D), threonine 4 to isoleucine (T4I), leucine 65 to proline (L65P), asparagine 80 to aspartic acid (N80D), threonine 137 to proline (T137P), or combination thereof.

12. The host cell of any one of claims 9 to 11, wherein the VKORc1 comprises two mutations G60D and VKORc1_{ΔAAR}.

13. The host cell of claim 6, wherein the at least one host cell-specific mutation is a mutation of at least one gene selected from the group consisting of a disulfide bond enzyme, insertase, ubiquinone biosynthesis gene, menaquinone biosynthesis gene, and cytoplasmic protease.

14. The host cell of claim 13, wherein the disulfide bond enzyme is *dsbB* or *dsbA*.

15. The host cell of claim 13, wherein the insertase is *yidC*.

16. The host cell of claim 13, wherein the cytoplasmic protease is *hslV* or *hslU*.

17. The host cell of claim 13, wherein the ubiquinone biosynthesis gene is selected from *ubiC* or *ubiE*.

18. The host cell of claim 13, wherein the menaquinone biosynthesis gene is *menA*.

19. The host cell of claim 15, wherein the *yidC* comprises a mutation at a residue selected from the group consisting of alanine 11 to threonine (A11T), threonine 362 to isoleucine (T362I), threonine 362 to alanine (T362A), threonine 362 to serine (T362S), threonine 362 to phenylalanine (T362F), threonine 362 to valine (T362V), threonine 362 to leucine (T362L), threonine 362 to glutamic acid (T362E), threonine 362 to arginine (T362R), threonine 362 to asparagine (T362N), threonine 362 to aspartic acid (T362D), threonine 362 to cysteine (T362C), threonine 362 to glutamine (T362Q), threonine 362 to glycine (T362G), threonine 362 to histidine (T362H), threonine 362 to methionine (T362M), threonine 362 to proline (T362P), threonine 362 to tryptophan (T362W), threonine 362 to tyrosine (T362Y), threonine 362 to lysine (T362K), arginine 366 to isoleucine (R366I), threonine 373 to isoleucine (T373I), glutamine 429 to isoleucine (Q429I), threonine 474 to isoleucine (T474I), glycine 512 to serine (G512S), serine 520 to isoleucine (S520I), asparagine 521 to isoleucine (N521I), and glutamine 527 to isoleucine (Q527I), or combination thereof.

20. The host cell of claim 19, wherein the *yidC* comprises a mutation at T362I.
21. The host cell of any one of claims 19 to 20, wherein the *yidC* comprises a double mutation at T362I and T373I.
22. The host cell of any one of claims 19 to 21, wherein the *yidC* comprises a double
5 mutation at T362I and G512S.
23. The host cell of any one of claims 19 to 22, wherein the *yidC* comprises a mutation at T362D, T362C, T362Q, T362G, T362H, T362M, T362P, T362W, T362Y, T362N, or T362R supplemented with a plasmid coding for YidC_{WT}.
24. The host cell of claim 16, wherein the *hslV* comprises a mutation at residue cysteine
10 160 to tyrosine (C160Y) or threonine 163 to isoleucine (T163I).
25. The host cell of claim 16, wherein the mutation is a deletion of *hslV* or *hslU*.
26. The host cell of claim 14, wherein the mutation is a deletion of *dsbB* or *dsbA*.
27. The host cell of claim 14, wherein the *dsbA* comprises a mutation at residue cysteine 33 to alanine (C33A).
- 15 28. The host cell of claim 18, wherein the mutation is a deletion of *menA*.
29. The host cell of claim 1, wherein the host cell further comprises a reporter.
30. The host cell of claim 29, wherein the reporter is β -galactosidase.
31. The host cell of any one of claims 29 to 30, wherein the β -galactosidase is a disulfide-bond sensitive enzyme.
- 20 32. The host cell of claim 31, wherein the disulfide-bond sensitive enzyme is β -gal^{dsb}.
33. The host cell of claim 1, wherein said exogenous nucleic acid molecule is under the control of a promoter.
34. The host cell of claim 33, wherein said promoter is a constitutive promoter or an inducible promoter.
- 25 35. The host cell of claim 34, wherein said inducible promoter is an isopropyl β -D-thiogalactopyranoside (IPTG)-inducible promoter.
36. A polypeptide expressed by the host cell of claim 1.
37. A cell culture of the host cell of claim 1.
38. A membrane preparation of a host cell of claim 1.
- 30 39. A method of ligand screening, drug screening, protein capturing, protein purification, immunization, or a biophysical study, wherein the improvement comprises: utilizing the host cell of claim 1, for ligand screening, drug screening, protein capturing and purification, immunization, biophysical studies.

Figure 1





Figure 2
A



B





Figure 2 (cont.)

C



D





Figure 3

A



B





Figure 4

A



B





Figure 4 (cont.)

C

anti-T7 tag (VKORc1)



anti-FLAG tag (DsbA)

(overexposed)




Figure 5




Figure 6




Figure 7




Figure 8




Figure 9




Figure 10
A




Figure 10 (cont.)
B




Figure 10 (cont.)

C




Figure 10 (cont.)
C





Figure 11



INTERNATIONAL SEARCH REPORT

International application No
PCT/US2016/061509

A. CLASSIFICATION OF SUBJECT MATTER
INV. C07K14/705 C12R1/19 C12N9/04
ADD.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
C07K C12R C12N

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)

EPO-Internal, BIOSIS, COMPENDEX, Sequence Search, EMBASE, FSTA, WPI Data

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	Xiaoyun Wang ET AL: "Membrane Topology and Mutational Analysis of Mycobacterium tuberculosis VKOR, a Protein Involved in Disulfide Bond Formation and a Homologue of Human Vitamin K Epoxide Reductase", Antioxid. Redox Signal, 18 February 2011 (2011-02-18), pages 1413-1420, XP055214948, DOI: DOI: 10.1089=ars.2010.3558 Retrieved from the Internet: URL:http://online.liebertpub.com/doi/pdfplus/10.1089/ars.2010.3558 [retrieved on 2015-09-21] cited in the application	1-3,5-8, 13,14, 26,29, 33-39
Y	the whole document	1-9, 13-39
	-/--	

☒ Further documents are listed in the continuation of Box C.

☒ See patent family annex.

* Special categories of cited documents :

"A" document defining the general state of the art which is not considered to be of particular relevance

"E" earlier application or patent but published on or after the international filing date

"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

"O" document referring to an oral disclosure, use, exhibition or other means

"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"&" document member of the same patent family

Date of the actual completion of the international search

22 March 2017

Date of mailing of the international search report

11/04/2017

Name and mailing address of the ISA/

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040,
Fax: (+31-70) 340-3016

Authorized officer

Madruga, Jaime

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2016/061509

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
	-& Xiaoyun Wang ET AL: "Supplementary Data to: Membrane Topology and Mutational Analysis of Mycobacterium tuberculosis VKOR, a Protein Involved in Disulfide Bond Formation and a Homologue of Human Vitamin K Epoxide Reductase", Antioxid. Redox Signal, 15 April 2011 (2011-04-15), pages 1413-1420, XP055357465, Retrieved from the Internet: URL:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3061198/bin/Supp_Data.pdf [retrieved on 2017-03-22] the whole document -----	
X	FRANK JAENECKE ET AL: "Membrane Composition Influences the Activity of in Vitro Refolded Human Vitamin K Epoxide Reductase", BIOCHEMISTRY, vol. 54, no. 42, 3 October 2015 (2015-10-03), pages 6454-6461, XP055356833, US ISSN: 0006-2960, DOI: 10.1021/acs.biochem.5b00716 the whole document	1-9, 33-39
Y	-& Frank Jaenecke ET AL: "Supporting Information: Membrane composition influences the activity of in vitro refolded human vitamin K epoxide reductase", Biochemistry, 27 October 2015 (2015-10-27), page 6454, XP055357513, United States Retrieved from the Internet: URL:http://pubs.acs.org/doi/suppl/10.1021/acs.biochem.5b00716/suppl_file/bi5b00716_si_001.pdf [retrieved on 2017-03-22] the whole document -----	1-9, 13-39
X	WO 2012/088222 A2 (UNIV NORTH CAROLINA [US]; TIE JIANKE [US]; STAFFORD DARREL W [US]) 28 June 2012 (2012-06-28)	1-9,11, 13,14, 26,29, 33-39
Y	pages 4,10,27; claims pages 72,73; figures 8, 34; examples the whole document ----- -/--	1-9, 13-39

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2016/061509

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 2012/104494 A1 (OULUN YLIOPISTO [FI]; RUDDOCK LLOYD [FI]; HATAHET FERAS [FI]) 9 August 2012 (2012-08-09)	1-4,8,9, 36-39
Y	pages 17-19; claims; examples; sequence 10 the whole document	1-9, 13-39
X	----- WO 2010/045381 A2 (HARVARD COLLEGE [US]; BECKWITH JONATHAN [US]; DUTTON RACHEL [US]; BOYD) 22 April 2010 (2010-04-22)	1-9,14, 26,36-39
Y	the whole document paragraphs [0040][0241]], [[0225]] - [[0228]], [[0239]] paragraphs [[0040]], [[0149]]; claims; example 2	1-9, 13-39
Y	----- AMANDA RAINE ET AL: "Targeting and insertion of heterologous membrane proteins in E. coli", BIOCHIMIE, vol. 85, no. 7, 1 August 2003 (2003-08-01) , pages 659-668, XP055357399, FR ISSN: 0300-9084, DOI: 10.1016/S0300-9084(03)00130-5 the whole document	1-9, 13-39
Y	----- BRENT L. NANNENGA ET AL: "Reprogramming chaperone pathways to improve membrane protein expression in Escherichia coli", PROTEIN SCIENCE, vol. 20, no. 8, 1 June 2011 (2011-06-01), pages 1411-1420, XP055357391, US ISSN: 0961-8368, DOI: 10.1002/pro.669 the whole document	1-9, 13-39
X,P	----- FERAS HATAHET ET AL: "Altered Escherichia coli membrane protein assembly machinery allows proper membrane assembly of eukaryotic protein vitamin K epoxide reductase", PROCEEDINGS NATIONAL ACADEMY OF SCIENCES PNAS, vol. 112, no. 49, 23 November 2015 (2015-11-23), pages 15184-15189, XP055356816, US ISSN: 0027-8424, DOI: 10.1073/pnas.1521260112 the whole document ----- -/--	1-39

INTERNATIONAL SEARCH REPORT

International application No
PCT/US2016/061509

C(Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT

Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	JIAN-KE TIE ET AL: "Human Vitamin K Epoxide Reductase and Its Bacterial Homologue Have Different Membrane Topologies and Reaction Mechanisms", JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 287, no. 41, 24 August 2012 (2012-08-24), pages 33945-33955, XP055356824, US ISSN: 0021-9258, DOI: 10.1074/jbc.M112.402941 the whole document -----	1-39
A	BOYD D ET AL: "The role of charged amino acids in the localization of secreted and membrane proteins", CELL, CELL PRESS, US, vol. 62, no. 6, 21 September 1990 (1990-09-21), pages 1031-1033, XP023884574, ISSN: 0092-8674, DOI: 10.1016/0092-8674(90)90378-R [retrieved on 1990-09-21] the whole document -----	1-39

INTERNATIONAL SEARCH REPORT

Information on patent family members

International application No

PCT/US2016/061509

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 2012088222 A2	28-06-2012	EP 2655607 A2	30-10-2013
		US 2013337504 A1	19-12-2013
		WO 2012088222 A2	28-06-2012

WO 2012104494 A1	09-08-2012	EP 2670844 A1	11-12-2013
		US 2014342398 A1	20-11-2014
		WO 2012104494 A1	09-08-2012

WO 2010045381 A2	22-04-2010	US 2011243958 A1	06-10-2011
		WO 2010045381 A2	22-04-2010
